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ABSTRACT 
The standard anti-retroviral drugs (ARVs) used for the treatment of HIV/AIDS have 
significant side effects resulting in a lack of adherence and the emergence of multi-
drug resistant viral strains. These drugs are also expensive, making it essential to 
investigate all alternatives to classical HIV/AIDS treatment. A wide variety of non-
conventional medicines are used by patients for the treatment HIV and for symptoms 
associated with HIV. So long as they are safe and effective, traditional, 
complementary and alternative medicines (TCAMs) may be considered more 
advantageous for developing countries as they are relatively cheap, more accessible 
and widely accepted by local populations.  
 
The aim of this study was to determine the prevalence of TCAM use in HIV-positive 
patients, prior to, and during ARV therapy. 
 
The study was exploratory, cross sectional and observational in nature. Participants 
were selected via convenience sampling from the Nelson Mandela Bay Municipality, 
and included 244 HIV-positive patients, 29 health care professionals (HCPs) and 30 
traditional, complementary and alternative practitioners (TCAMPs).  
 
A wide variety of TCAMs were used by the sample population. These medicines 
were more commonly used by non-ARV patients (36%) compared with ARV patients 
(22%). A significant statistical difference in TCAM use between the ARV and non-
ARV population was found in relation to education, employment, period of status 
awareness, patient opinion of personal health and the reasons for TCAM use. 
Amongst the HCPs, 24% recommended TCAM use prior to ARVs, and 55% were 
aware of patients self-prescribing before and during ARV treatment. Amongst the 
TCAMPs, 90% provided a wide range of TCAMs for HIV, with some giving 
consideration to conventional management. 
 
TCAMs are commonly used by HIV-positive patients on ARVs, as well as by those 
not on ARVs. These medicines are also the preferred form of treatment for those not 
seeking conventional treatment. TCAMs are widely available and recommended by 
TCAMPs as well as some HCPs. Due to public health concerns, clinical trials of the 
viii 
 
widely used TCAMs are crucial in order to establish the safety and efficacy of these 
medicines in HIV.  
 
 
Key words: Traditional medicine, complementary medicine, alternative medicine, 
herbal medicine, conventional medicine, HIV/AIDS, ARV treatment, pre-ARV 
treatment, anti-HIV activity. 
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Chapter 1 
INTRODUCTION 
  
1.1. BACKGROUND 
 
The Human Immunodeficiency Virus (HIV) has resulted in a worldwide epidemic that 
is responsible for causing Acquired Immunodeficiency Syndrome (AIDS). Since it 
was first recognised in 1981, HIV has been reported to have infected almost 60 
million people. AIDS is estimated to have caused the deaths of more than 25 million 
people, making it one of the most destructive epidemics in recorded history.   In 
2008, the number of people in the world living with HIV was estimated to be 33.4 
million, 20% higher than the number in 2000.  Of the 33.4 million, 15.7 million were 
reported to be women and 2.1 million children under the age of 15 years. (UNAIDS 
and WHO 2009a, 2009b) 
 
The scale and trends of the epidemic vary considerably in different regions of the 
world, with southern Africa being the most seriously affected. In 2007, this sub-
region accounted for 35% of all people living with HIV and almost one third (32%) of 
all new HIV infections and AIDS deaths globally (UNAIDS 2007). South Africa, with 
an estimated 5.7 million people with HIV, continues to have the largest epidemic in 
the world (UNAIDS 2010). 
 
HIV is a retrovirus that is responsible for causing AIDS, a condition in which the 
immune system of the infected individual becomes compromised, hence making the 
patient susceptible to life threatening opportunistic infections.  
 
Treatment with antiretroviral drugs (ARVs) has been effective in prolonging the lives 
of HIV-positive patients who would have eventually progressed to stages 3 and 4 of 
AIDS. However, the drugs do not cure the infection; they merely arrest the 
progression of the condition. These drugs are also potentially toxic and have adverse 
side effects which can result in a lack of adherence. An alteration of blood drug 
levels and/or development of drug-resistant strains of the virus are therefore highly 
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possible, thus undermining effective treatment and posing public health risks. 
(Harnett 2004) 
 
In the absence of an AIDS defining illness, the Department of Health (2010) 
recommends initiation of ARVs at a CD4 count of 200 cells/mm3. With a normal CD4 
count being above 450 cells/mm3 (Bower et al. 2004), initiation of ARVs at 200 
cells/mm3 makes patients highly susceptible to opportunistic infections by the time 
they meet the criteria for ARV therapy (Aid for AIDS 2007). Furthermore, besides the 
toxicity and adverse side effects, ARVs are also very expensive.  
 
Investigations of cost-effective alternatives with lower side effect profiles are 
therefore critical especially in developing countries, where the majority of patients 
are unable to commence ARV treatment at a recommended earlier stage of 350 CD4 
cells/mm3 (Warlick 2008). Often with a lower education level, patients are unable to 
understand the necessity of adherence to medication with unpleasant adverse 
effects such as that of ARVs (Buckalew 2006). As a result, the impact of the 
HIV/AIDS epidemic, particularly at the level of households is proving to be very 
dramatic and is having a devastating social and economic impact. Families lose 
income earners, household expenditure is redirected to cover non-food items such 
as medical costs and funerals, children are taken out of schools for lack of fees or to 
care for sick relatives, workers have to take time off to provide care for terminally ill 
family members, resources may have to be shared with more dependents, and 
productive assets are sold off. (AIDS Foundation 2005)  
 
In Africa, many HIV-positive people, in resource-limited settings, depend on and 
choose traditional healers for psychosocial counselling and healthcare (UNAIDS 
2002). This is because African traditional healers are not only more available and 
accessible than health care professionals (HCPs), but the majority of the local 
population also strongly believe in the usefulness and power of traditional medicine 
(Homsy et al. 2004). Herbal remedies have been widely prescribed by traditional 
healers for the treatment of HIV (Dickinson 2008). It is therefore important to 
investigate the extent to which herbal and non-herbal treatments are being offered 
by traditional healers to HIV-positive patients.  
 
3 
 
 
Patients also self prescribe over-the-counter herbal remedies from pharmacies and 
herbalists for the treatment of HIV, prior to and during ARV therapy (Lunat 2008). In 
South Africa, any substance purporting to treat a disease or its symptoms is 
regulated by the Medicines and Related Substances Act 101 of 1965, and is subject 
to a rigorous registration process that includes providing proof of properly conducted 
clinical trials. However, labelling a medicine "complementary" appears to exempt it 
from this rigorous process. Registration of complementary herbal medicine simply 
involves submitting a dossier listing the product's contents and the claims for its 
efficacy to the regulatory authority, the Medicines Control Council (MCC). 
Furthermore, despite insufficient evidence of safety or efficacy, Sutherlandia and 
Hypoxis have been previously recommended by the Department of Health in South 
Africa for use in HIV. (Mills et al. 2005) HIV-positive patients therefore have easy 
access to herbal remedies and may even be using them in accordance with 
government recommendations. 
 
Prescribing herbal remedies, by some HCPs, has also become common practice for 
the management of those who do not yet meet the criteria to begin ARV therapy.1 
The aim of using herbal immune modulators by clinical practitioners is to attempt to 
reverse the progressive immune deficiency caused by the human immunodeficiency 
virus, and also to try and restore specific immune responses that are lost in patients 
with chronic infection. A preliminary study by Lunat (2008) showed that patients were 
being prescribed Sutherlandia frutescens and Lobostemon fruticosus for the 
management of HIV, prior to ARV therapy, at the Uitenhage & Dispatch Independent 
Practitioners Association (UDIPA) Clinic, a private HIV/AIDS clinic in Uitenhage, 
South Africa. The study also showed that herbalists were prescribing Sutherlandia, 
Hypoxis hemerocallidea and Echinacea to patients, overlooking the possibility of 
patients also being on ARVs.  
 
Some of the South African HIV-positive population, especially those of European and 
Asian descent may choose other complementary and alternative therapies to try and 
manage their condition (Peltzer et al. 2008). Some complementary and alternative 
therapies may include for example homeopathic therapies, aromatherapy, 
                                                
1 Personal communication with Sister C Naidoo at UDIPA Clinic in Uitenhage on 14 February 2008  
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chiropractic care, reflexology, faith healing methods, meditation, spiritual practices or 
prayer, exercise and traditional Chinese medicine such as acupuncture. 
 
With concurrent use of TCAMs, a matter of concern would be the concept of pill 
burden. Pill burden is a term that refers to the number of tablets, capsules or other 
dosage forms that a patient takes on a regular basis. A high pill burden may result in 
an increased number of adverse effects and possibly low adherence to medication. 
Patients on ARVs already have a high pill burden with at least three different drug 
regimens being dosed daily. As a result, with a possibly increased social bias 
towards TCAMs, adherence towards allopathic conventional medicines such as 
ARVs may further decline. 
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1.2. AIM 
The aim of this study was to determine the prevalence of traditional, complementary 
and alternative medicines use in HIV-positive patients, prior to, and during ARV 
therapy, in the Nelson Mandela Bay Municipality.  
1.3. OBJECTIVES 
The objectives of this study were to determine the: 
• allopathic and non-allopathic agents most commonly prescribed to HIV-
positive patients by HCPs; 
• TCAMs most commonly recommended to HIV-positive patients by traditional, 
complementary and alternative medicine providers/practitioners; 
• extent of use of TCAMs by HIV-positive patients prior to and during ARV 
therapy; 
• extent to which TCAM use is disclosed by patients to their HCPs; and 
• general attitudes of HCPs, TCAM providers/practitioners and patients towards 
the use of TCAMs in HIV/AIDS 
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Chapter 2 
HIV MANAGEMENT: CONVENTIONAL 
2.1. THE HUMAN IMMUNODEFICIENCY VIRUS   
Since its discovery in 1981, there was an initial reluctance to acknowledge the 
connection between the Human Immunodeficiency Virus (HIV) and Acquired 
Immunodeficiency Syndrome (AIDS). There is now clear evidence to prove that HIV 
is, in fact, the etiological agent of AIDS.  After its discovery, by 1984 HIV had been 
isolated and described, and the mechanisms of transmission were being identified 
(Nowak and Handford 2004). It is now known that there are two major types of HIV: 
HIV-1 which is responsible for most of the international epidemic and more prevalent 
in the United States and Europe (Bauman 2007); and HIV-2, which is more prevalent 
in West Africa (Nowak and Handford 2004). The virus mainly targets T-helper 
lymphocytes and cells of the macrophage lineage thereby infecting key cells and 
significantly weakening the hosts’ immune system. HIV-1 appears to reproduce 
faster, and produces immunodeficiency and AIDS with higher frequency than HIV-2. 
(Bauman 2007)  
 
Transmission of the virus may occur through unprotected sexual contact; direct 
contamination of blood, as occurs with open wounds or between intravenous drug 
abusers via contaminated needles; and transmission from mother to child at birth or 
during breast feeding. (Nowak and Handford 2004) 
 
The virus, a member of the lentivirus subfamily of retroviruses, has an envelope 
characterised by two antigenic glycoproteins, gp120 and gp41 (Refer Figure 2.1). 
Following transmission of the virus into the host, the gp120 binds to CD4 receptor 
molecules on the host cell. The gp120-CD4 complex then binds to a chemokine 
receptor (CXCR4 on T cells and CCR5 on macrophages) which removes the gp120 
from the virus. The antigenicity of this glycoprotein can change during the course of 
prolonged infection, thereby making an effective antibody response against it very 
difficult. The gp41 glycoprotein promotes fusion of the viral envelope to a target cell 
allowing the introduction of the HIV capsid into the cytoplasm (Refer Figure 2.1). The 
effects of these structural characteristics, which promote antigenic variability and the 
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ability to fuse with host cells, impede immune clearance of the virus from the infected 
individual. (Bauman 2007) 
 
 
Figure 2.1: The HIV virus (Adapted from: Dennis 2008) 
 
Uncoating of the capsid occurs following its introduction into the cell, thereby 
releasing, into the cytoplasm, the HIV RNA genome as well as the enzymes, reverse 
transcriptase, protease and integrase. Retroviruses such as HIV have the ability to 
reverse the usual direction of genetic information within the host cell in order to 
produce proteins. The reverse transcriptase enzyme migrates along the viral RNA in 
the cytoplasm to produce a complementary strand of DNA2. The reverse 
transcriptase, on completion of the first DNA strand, constructs a second strand 
                                                
2
 Reverse transcriptase is very prone to errors, making about five errors per genome, and thereby 
generating numerous new antigenic variations of HIV during the course of infection (Bauman 2007: 
720). 
RNA 
Reverse 
Transcriptase 
Viral membrane 
(Lipid layer) 
Transmembrane 
glycoprotein (gp41) 
Transmembrane 
glycoprotein (gp120) 
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using the first one as a template. (Hutchinson 2001) The double stranded viral DNA 
then enters the nucleus as a provirus and gets incorporated into the human 
chromosome with the help of viral integrase (Refer Figure 2.2). Once incorporated, 
HIV can be transcribed and replicated in the same way as any other cellular gene. 
(Bauman 2007) The incorporated provirus has genetic switches called Long 
Terminal Repeats (LTRs) which serve as the binding sites for regulatory proteins. 
The binding of these regulatory proteins causes the activation of the hosts RNA 
Polymerase II, which then causes the transcription of the provirus to complementary 
RNA strands.  Some of these strands are cut into segments and spliced into lengths 
appropriate for the translation of viral regulatory proteins necessary for HIV 
production. Unspliced RNA transcripts become new viral strands and migrate into 
the cytoplasm where they are incorporated into the viral core protein, together with 
reverse transcriptase and integrase. (Hutchinson 2001)  
 
Protease then causes the final assembly for the formation of virulent HIV (Bauman 
2007) (Refer Figure 2.2). 
 
9 
 
 
 
Figure 2.2: HIV life cycle (Source: Morse 2008) 
 
2.2. PROGRESSION OF UNMANAGED HIV 
Following primary infection, rapid viral replication begins within the body, with 
accompanying fever, fatigue, weight loss, diarrhoea and body aches (Bauman 2007). 
During this acute phase of infection, the number of CD4 cells decreases while viral 
load increases dramatically, with HIV copies spreading throughout the body and 
seeding in lymphoid organs (Refer Figure 2.3) (Fauci 2009).  
 
Two to four weeks after exposure to the virus, the immune system responds by 
producing killer T cells and B-cell produced antibodies (Fauci 2009). Almost a billion 
viruses are destroyed each day by the immune system and in the process about a 
100 million of the immune cells are killed by the viruses and cytotoxic T cells 
(Bauman 2007). During this period, the CD4 count increases considerably, up to 
normal levels in some individuals (Fauci 2009) (Refer Figure 2.3).  
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Following significant recuperation of CD4 cells, a state of clinical latency is reached 
(Refer Figure 2.3) during which the individual remains asymptomatic and unaware of 
the infection (Bauman 2007). This stage may last for several years, despite the 
continuing replication of HIV in the lymphoid tissue (Fauci 2009). 
 
 
2.3. ACQUIRED IMMUNODEFICIENCY SYNDROME 
As HIV continues to replicate, the immune system is unable to adequately replenish 
CD4 cells and therefore the CD4 count declines to a level that severely impairs the 
immune system (Bauman 2007). Constitutional symptoms (Refer Figure 2.3) which 
affect the general well being of the patient, such as weight loss, chills, fever and 
vomiting begin to develop (Pantaleo et al. 1993). As the immune system continues to 
deteriorate, the patient becomes highly susceptible to life threatening opportunistic 
infections, and develops the condition known as Acquired Immunodeficiency 
Syndrome (AIDS). Opportunistic infections associated with AIDS include 
Pneumocystis jiroveci pneumonia (PCP), Cytomegalovirus infections, 
Mycobacterium tuberculosis (TB), and fungal infections such as those by 
Histoplasma capsulatum, Coccidioides immitis and Cryptococcal infections. Other 
Figure 2.3: Progression of unmanaged HIV  
(Source: Pantaleo et al. 1993: 328) 
11 
 
 
opportunistic infections include Toxoplasmosis, Herpes simplex virus infections, 
gastrointestinal protozoal infections and Kaposi’s sarcoma. (Nowak and Handford 
2004) As shown in Figure 2.3 above, unmanaged-HIV progresses over a period of 
years from primary infection until the viral load increases dramatically, and the 
immune system, reflected by the CD4 count, becomes so compromised that the 
patient may no longer be able to survive without medical intervention. 
 
2.4. HIV MANAGEMENT 
The United Nations Security Council, in January 2000, identified AIDS in Africa as a 
major human security concern, as well as an obstacle to development (UNAIDS 
2001). A considerable increase in political commitment occurred thereafter and a 
huge increase in funding, from US$300 million in 1996 to US$10 billion in 2007, 
helped strengthen the response to HIV in all the most affected countries (UNAIDS 
2007). Despite this the World Disasters Report of 2008 (Knight 2008) for the first 
time focused on a single disease, since for a number of countries, and for a 
significant number of people, the HIV epidemic continues to be a major disaster.  
 
2.4.1. Conventional treatment 
The CD4 count of an infected individual is the most clinically useful laboratory 
indicator to predict the degree of immune suppression and the stage of the disease, 
and it assists in deciding when treatment should be initiated. However, CD4 counts 
are not a precise indication of the progression of infection and patients may remain 
asymptomatic despite very low CD4 counts. CD4 counts may also be affected by 
other infections such as tuberculosis, and in pregnancy, the count falls by up to 25% 
and may vary from day to day by up to 20%. Due to this variability in CD4 counts, 
major therapeutic decisions should not be based on a single count or on CD4 counts 
alone. Viral load is a more precise indication of the progression of infection as it 
measures the amount of HIV in the blood and indicates how fast the virus is 
replicating (Refer Figure 2.3). It also has a prognostic value, as patients with a high 
viral load will experience a more rapid decline in the CD4 count, while those with a 
lower viral load have a slower decline. (Aid for AIDS 2007) 
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The WHO disease staging system for HIV infection is used in resource limited 
settings such as Africa and Asia, in order to determine the stage of the infection 
(UNAIDS and WHO 2007). These stages are detailed as follows: 
 
Table 2.1: WHO disease staging system for HIV infection 
Clinical stage Symptoms 
Stage 1 
Primary HIV infection 
• CD4 count initially decreases and usually 
increases again, usually to >500 cells/mm3 
• Flu-like symptoms; thereafter asymptomatic 
• Persistent generalized lymphadenopathy 
• ARV therapy not recommended at this stage 
unless patient is showing signs and symptoms 
of stages 3 or 4 
Stage 2 
Clinically asymptomatic 
stage 
• CD4 count drops significantly and is usually 
between 200-350 cells/mm3 
• Moderate unexplained weight loss (under 10% 
of presumed or measured body weight) and 
mild symptoms of opportunistic infections 
• ARV therapy is recommended at this stage 
• However, not eligible for ARV treatment in 
South Africa unless pregnant or co-infected with 
TB (Department of Health 2010) 
Stage 3 
Symptomatic HIV 
infection 
• CD4 count usually drops to about 200 
cells/mm3 
• Patient at this stage is highly susceptible to 
opportunistic infections and symptoms are more 
severe 
• Eligible for ARV treatment in South Africa 
(Department of Health 2010) 
Stage 4 
Progression from HIV to 
AIDS 
• CD4 count usually much lower than 200 
cells/mm3 
• Severe opportunistic infections and HIV related 
tumours develop at this stage 
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Clinical stage Symptoms 
• ARV treatment is highly recommended 
• Eligible for ARV treatment (Department of 
Health 2010) 
(Adapted from Aid for AIDS 2007: 8; UNAIDS and WHO 2007; and Warlick 2008). 
 
2.4.1.1. Management prior to antiretroviral treatment 
The South African National Department of Health guidelines (2010) stipulate 
initiation of ARVs only at a CD4 count of 200 cells/mm3, or if the patient presents with 
a WHO stage 4 AIDS defining illness (Refer standard practice below for ART 
eligibility). The CD4 count of an un-infected individual normally ranges from 450 to 
1660 cells/mm3 (Bower et al. 2004). Therefore, prior to eligibility for ARV treatment, 
the weakening immune system allows infectious microorganisms to go unnoticed 
and proliferate, thereby allowing opportunistic infections to occur. There is therefore 
a need for prophylaxis against opportunistic infections associated with HIV/AIDS, 
prior to antiretroviral treatment.  
 
i. Co-trimoxazole  
Co-trimoxazole is a safe, low cost, widely available, broad spectrum 
antimicrobial agent with evidence that it substantially contributes to the 
improvement of quality of life of HIV positive patients. Since the early 1990s, 
the use of co-trimoxazole for prophylactic purposes has been part of the 
standard of care for HIV positive patients in developed countries. This has 
now been adopted by many developing countries as there is substantial 
evidence proving the necessity of use in immunocompromised individuals. 
(Federal Ministry of Health 2006)  The active ingredients of co-trimoxazole - 
sulfamethoxazole and trimethoprim - target a range of aerobic gram-positive 
and gram-negative organisms, fungi and protozoa.  
 
Sulfamethoxazole, a sulphonamide antibiotic, is a structural analogue of p-
aminobenzoic acid (PABA). It competitively inhibits dihydropteroate synthase, 
thereby inhibiting growth by reversibly blocking folic acid synthesis in 
susceptible organisms. Folic acid synthesis is an essential step in the 
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production of purines and in the synthesis of nucleic acids. Trimethoprim 
further inhibits folic acid synthesis by inhibiting dihydrofolate reductase, 
thereby having a synergistic effect with sulfamethoxazole in inhibiting nucleic 
acid synthesis. (Chambers 2004) 
 
Co-trimoxazole is active against Pneumocysitis jiroveci pneumoniae (PCP), 
Streptococcus pneumoniae, non-typhoidal Salmonella, Isospora belli, 
Toxoplasma gondii, Plasmodium Falciparum and enteric gram negative 
organisms such as E.coli and Shigella species.  These organisms commonly 
cause illness in HIV positive patients. In developed countries, the major 
benefit of co-trimoxazole prophylaxis is related to the reduction of episodes of 
PCP. Studies on African populations show a significant reduction in mortality 
from PCP, malaria, non-typhoidal Salmonelosis, Streptococcus pneumoniae, 
diarrheal diseases and also an improvement in the CD4 cell count of HIV 
positive patients. (Federal Ministry of Health 2006)   
 
Some countries, such as South Africa, choose to adopt a CD4 threshold of 
200 cells/mm3, provided the patient is asymptomatic (Department of Health 
2010). However, this option is recommended only if the main targets for co-
trimoxazole prophylaxis are PCP and toxoplasmosis. Raising the CD4 
threshold to 350 cells/mm3 will help prevent a wider range of opportunistic 
infections, thereby improving the overall quality of life of HIV positive patients. 
Another approach chooses to treat all individuals with HIV irrespective of CD4 
count or WHO clinical stage. This strategy may be considered in settings with 
high prevalence of HIV and limited health infrastructure. However, lifelong use 
of co-trimoxazole prophylaxis for all people living with HIV needs to be 
weighed against the challenges of maintaining long-term adherence and the 
potential for emergence of drug-resistant pathogens. (WHO 2005)  
 
ii. Fluconazole 
Oropharyngeal candidiasis (OPC) is the most common opportunistic infection 
amongst HIV-positive individuals (Goldman et al. 2005). OPC and other 
fungal infections, such as cryptococcal meningitis, occur more frequently in 
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HIV/AIDS patients living in resource limited settings with little or no access to 
ARVs (Kerdpon et al. 2003).  Without the availability of therapy for immune 
reconstitution, prophylaxis against these opportunistic infections may be the 
only means of improving the quality and longevity of patients’ lives (Nelson 
and John 2004). 
 
Primary prophylaxis with azole antifungals has been shown to be effective in 
reducing the incidence of fungal infections including cryptococcal meningitis 
and candidiasis in those with HIV infection (Nelson and John 2004). 
Fluconazole is the azole of choice in the treatment and secondary prophylaxis 
of cryptococcal meningitis, and is the agent most often used for the treatment 
of candidiasis (Sheppard and Lampiris 2004).  
 
The antifungal activity of fluconazole results from the reduction of ergosterol 
synthesis by inhibition of fungal cytochrome P450 enzymes. Its specificity 
results from the greater affinity for fungal rather than for human cytochrome 
P450 enzymes. It has a high degree of water solubility and good 
cerebrospinal fluid penetration. Unlike other azoles, its oral bioavailability is 
high and has the least effect of all the azoles on the hepatic microsomal 
enzymes. Due to fewer hepatic enzyme interactions and better 
gastrointestinal tolerance, fluconazole has the widest therapeutic index of the 
azoles, permitting more aggressive dosing in a wide variety of fungal 
infections. (Sheppard and Lampiris 2004) 
 
Although prophylactic use of fluconazole has been demonstrated to reduce 
fungal disease in HIV/AIDS patients, the emergence of fluconazole resistant 
fungi has raised concerns about this indication (Sheppard and Lampiris 2004). 
However, these concerns are addressed in a large randomised, controlled, 
prospective study involving 829 HIV-positive subjects on fluconazole therapy. 
The proportion of oropharyngeal and/or esophageal infections that were 
clinically refractory or resistant to fluconazole, after a median of approximately 
two years of follow-up, was higher amongst patients receiving continuous 
fluconazole therapy (9%) than amongst those receiving episodic fluconazole 
therapy (2%), but the risk of any infection was four times greater in the latter 
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group. The risk of a clinically refractory or resistant oropharyngeal or 
esophageal candidal infection was essentially the same in both groups, at 
slightly more than 4%. (Goldman et al. 2005) “The inclusion of 829 subjects, a 
median follow-up duration of 24 months, and very similar rates of fluconazole 
refractory mucosal Candidal infections (FRIs) in both the continuous and 
episodic fluconazole treatment arms, makes it unlikely that the study lacked 
sufficient power to detect a meaningful difference in the incidence of FRIs by 
treatment assignment” (Goldman et al. 2005). These results indicate that 
concern about resistance should not be a factor in the decision to provide 
prophylaxis in HIV positive patients (Bozzette 2005).  
 
iii. Vitamins 
Individuals in all stages of HIV infection have been shown to have low 
circulating concentrations of micronutrients, even in developed countries, 
where dietary micronutrient intake is high. Low micronutrient concentrations 
are associated with HIV disease progression, mortality and vertical viral 
transmission. (Austin et al. 2006)  
 
Higher dietary intake or supplementation of micronutrients has been shown to 
delay the progression of the condition (Tang et al. 1996). 
 
• Vitamin B-complex 
Vitamin B-complex is a combination of eight water soluble B vitamins 
which coexist in the same foods. These vitamins include thiamine (B1), 
riboflavin (B2), niacin (B3), pantothenic acid (B5), pyridoxine (B6), biotin 
(B7), folic acid (B9) and cyanocobalamin (B12). (Pitkin et al. 1998)  
 
Thiamine was the first to be identified amongst the B vitamins. It functions 
as a coenzyme in the metabolism of carbohydrates and branched-chain 
amino acids. A lack of thiamine causes the deficiency disease known as 
beriberi (Pitkin et al. 1998). Thiamine deficiency has been reported to 
occur in both, asymptomatic and advanced stages of HIV (Muri et al. 
17 
 
 
1998). Clinical signs of thiamine deficiency include irritability, muscle 
weakness, confusion, apathy, anorexia and weight loss. (Pitkin et al. 1998)     
 
Riboflavin acts as a coenzyme in numerous metabolic pathways and in 
energy production. A deficiency of riboflavin causes sore throat, 
hyperaemia and edema of the pharyngeal and oral mucous membranes, 
cheilosis, angular stomatitis, glossitis, seborrheic dermatitis and 
normocytic anaemia associated with erythrocyte cytoplasia of the bone 
marrow. Severe riboflavin deficiency may impair the metabolism of 
pyridoxine. (Pitkin et al. 1998) Supplementation with riboflavin may help 
counter-act lactic acidosis associated with the use of the NRTI class of 
ARVs (Posteraro et al. 2001).       
 
Niacin refers to nicotinamide and derivatives that exhibit the activity of 
nicotinamide. In the form of coenzymes NAD and NADP, these forms of B 
vitamins have functions in numerous redox reactions of the human body. A 
condition known as pellagra develops in severe niacin deficiency. Pellagra 
is characterised by a loss of memory, fatigue, headache, apathy, 
depression, bright red tongue, diarrhoea, vomiting and a pigmented rash 
that develops symmetrically in areas exposed to sunlight. (Pitkin et al. 
1998) Amongst other reasons, niacin deficiency may also be associated 
with HIV infection. This is because interferon-gamma (IF-g) levels are 
usually elevated in HIV-positive patients. IF-g stimulates the enzyme 
indoleamine 2,3 deoxygenase, which is responsible for the breakdown of 
tryptophan, a precursor of niacin. (Drake 2007) Supplementation with 
niacin has been reported to reduce the rate of progression of HIV to AIDS 
in HIV-positive men (Tang et al. 1996).  
 
Pantothenic acid is involved in the metabolism of fatty acids. Most tissues 
transport pantothenic acid into cells for the synthesis of CoA, an acyl 
carrier protein which is a component of the fatty acid synthase complex. A 
lack of pantothenic acid can cause irritability, restlessness, fatigue, apathy, 
malaise, sleep disturbances, abdominal cramps, nausea, vomiting and 
hypoglycemia. (Pitkin et al. 1998)    
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Pyridoxine functions as a coenzyme in the metabolism of glycogen and 
amino acids. A deficiency of pyridoxine may cause seborrheic dermatitis, 
microcytic anemia, epileptiform convulsions, depression, confusion and 
impaired platelet function. Pyridoxine deficiency may be responsible for a 
reduction in the levels of dopamine, serotonin and alpha-aminobutyric 
acid.  (Pitkin et al. 1998) An association between HIV and pyridoxine 
deficiency has been reported. A study carried out by Mantero and 
colleagues (1990) revealed a large percentage of their HIV-positive 
sample population lacked pyridoxine.  
 
Folic acid functions as a coenzyme in single carbon transfers for the 
metabolism of nucleic acids and amino acids. The coenzyme functions in 
reactions such as DNA synthesis, purine synthesis, the utilisation of 
formate and in amino acid interconversions (Pitkin et al. 1998). A 
deficiency in folic acid commonly occurs due to inadequate intake, but may 
also occur as a result of HIV infection (Remacha 2003). Folic acid 
deficiency initially results in a decreased erythrocyte folate concentration, 
rise in homocysteine concentration, and megaloblastic changes in the 
bone marrow. Macrocytic anaemia eventually develops in patients with 
long term folic acid deficiency. Hematocrit, haemoglobin and erythrocyte 
concentrations become depressed, and shortness of breath, headache, 
irritability, difficulty concentrating and fatigue may become apparent at an 
advanced stage of the anaemia. (Pitkin et al. 1998)         
 
Cyanocobalamin functions as a coenzyme for the conversion of 
homocysteine to methionine in a methyl transfer reaction. It also acts as a 
coenzyme for the conversion of l-methylmalonyl coenzyme A (CoA) to 
succinyl-CoA. A lack of cyanocobalamin may cause pernicious anaemia 
characterised by pallor of the skin associated with common symptoms of 
anaemia, fatigue, shortness of breath and palpitations. (Pitkin et al. 1998) 
Lack of this B12 vitamin may occur, amongst other reasons, as a result of 
HIV infection (Remacha 2003).    
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• Vitamin C 
Ascorbic acid and dehydroascorbic acid contribute to the biological 
activities of vitamin C. Ascorbic acid is a 6-carbon lactone that readily 
oxidizes in aqueous solution to its di-keto form, dehydroascorbic acid 
(Webb 2007). Foods rich in vitamin C include cherries, black currants, 
cruciferous vegetables, citrus fruits and strawberries.  
 
Vitamin C is a potent antioxidant, effectively quenching free radicals and 
protecting cell membranes and intracellular proteins from oxidative 
damage. It also facilitates iron absorption, the regeneration of vitamin E, 
and the use of calcium in bone. Vitamin C is associated with a wide range 
of immune related functions including an enhanced antibody response, 
neutrophil function, and mitogenic response in several animal models. 
(Webb 2007) Ascorbate has also been shown to inhibit several viruses 
such as the herpes virus, rhinovirus, and HIV (Harakesh et al. 1990).  
 
The benefits of vitamin C supplementation on reducing the incidence, 
severity and duration of the common cold are debatable. Vitamin C has 
been shown, in randomised control trials, to reduce the incidence of 
pneumonia by up to 85%. Early non-controlled studies in HIV positive 
individuals suggested that mega-dose (50-200 g/day) supplementation of 
vitamin C was associated with reduced severity and frequency of 
opportunistic infections, however, randomised control trials have not been 
conducted to prove this hypothesis. (Webb 2007) 
 
• Vitamin E 
Vitamin E represents a group of tocol and tocotrienol derivatives which 
exhibit tocopherol activity and are found in high concentrations in 
vegetable oils. Studies in animal models have shown vitamin E deficiency 
to be associated with impairments in cellular and humoral immunity. 
(Webb 2007) Vitamin E supplementation enhances macrophage function 
and CD4 T-cell activity and causes an increase in antibody production 
(Gore and Qureshi 1997). 
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The mechanisms for the immuno-modulatory effects of vitamin E possibly 
involve its antioxidant activity. Vitamin E is a lipid-soluble peroxyl 
scavenger which protects lipids from auto-oxidation. It helps stabilise 
immune cells by maintaining membrane fluidity and permeability and may 
therefore have protective benefits to the membranes of cells involved in 
the production of ROS via the respiratory burst. (Webb 2007)  
 
Vitamin E may also reduce ROS production by interfering with protein 
kinase C phosphorylation, inhibiting NADPH oxidase assembly, and post 
transcriptional modification of lipoxygenase enzymes (Tits et al. 2000). It 
may also attenuate age-related increases in prostaglandin E2, a T-cell 
suppression factor, via inhibition of cyclooxygenase 2 activity (Webb 
2007).  
 
A recent study by Schürks and colleagues (2010), reported a raised risk of 
haemorrhagic stroke with vitamin E supplementation.    
 
• Combination Vitamins 
A randomised control trial was carried out in 1998, in Canada, cited by 
Webb (2007), where the HIV positive patients received either a placebo or 
a combination supplement of 1000mg Vitamin C and 360mg Vitamin E. A 
trend towards a reduced viral load and decreased oxidative stress was 
observed in the patients receiving the vitamins when compared to those 
with placebo. Another study cited by Webb (2007), carried out on HIV 
positive women in Tanzania in 2004, showed multivitamin supplementation 
significantly reduced viral load, delayed disease progression and lowered 
mortality due to AIDS related complications. Prenatal and postnatal 
supplementation of HIV-positive mothers also showed a reduction in the 
transmission of HIV to infants via breast feeding. Furthermore, a study 
carried out in 2002, showed that a multivitamin combination of vitamin B, C 
and E reduces maternal and infant mortality, lowers the rate of mother to 
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child transmission, and provides long term beneficial effects on CD4 
counts and viral load (Mermin et al. 2005). 
 
Table 2.2 summarises the South African Department of Health’s guidelines for the 
prevention of opportunistic infections associated with HIV. 
 
Table 2.2: Prevention of opportunistic infections in HIV positive adults 
Agent/intervention Indication Disease prevented 
Trimethoprim-
sulfamethoxazole 
All symptomatic HIV 
positive individuals (WHO 
clinical stage 2, 3 or 4) or 
CD4 count below 200 
cell/mm3 or if there has 
already been an active 
infection of PCP, or HIV 
associated thrush, 
unexplained fever x 2 
weeks or toxoplasmosis. 
Treatment no longer 
needed once patient is on 
ART and CD4 > 200 
cells/mm3 for 6 months 
• Pneumocystis jiroveci 
pneumonia 
• Toxoplasmosis 
• Many bacterial 
infections 
• Diarrhoea caused by 
Isospora Belli or 
Cyclospora species 
• Malaria  
 
Fluconazole 
Amphotericin B 
CD4 count < 50 cells/mm3 
with high risk of 
Cryptococcosis, or if 
considered as part of the 
decision to treat other 
concomitant fungal 
infections 
• Cryptoccocosis 
• Candidiasis 
Multivitamins Poor appetite and/or 
financial constraints that 
compromise meeting the 
requirements for vitamins 
• General wellbeing 
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Agent/intervention Indication Disease prevented 
and minerals from diet 
alone  
Isoniazid HIV positive adults with no 
signs or symptoms of TB 
and a normal chest x-ray. 
Important to rule out active 
TB before initiating 
prophylaxis to prevent 
development of isoniazid 
resistance 
• Mycobacterium 
tuberculosis 
Acyclovir Individuals with frequent or 
severe recurrences can be 
administered daily 
suppressive therapy 
• Herpes simplex virus 
infections 
Hepatits B vaccine All susceptible (HBc or Hep 
BsAb negative) HIV positive 
individuals 
• Hepatitis B 
Influenza vaccine All HIV positive individuals. 
(Not recommended in those 
severely immuno-
compromised) 
• Influenza 
 
(Adapted from the National Department of Health Guidelines 2010) 
 
2.4.1.2. Antiretroviral treatment 
Since the discovery of HIV in 1981, many ground breaking events have occurred. 
The first commercial test for the detection of HIV was made available in 1985. In 
1987, zidovudine, the first antiretroviral drug was released. The 2nd and 3rd ARVs, 
didanosine and zalcitabine, were released in 1991 and 1992 respectively. 
Saquinavir, the first protease inhibitor was released in 1995 and a triple-drug therapy 
(highly active antiretroviral therapy) with significant benefit in HIV management was 
recommended in 1998. (Biswas and Sudharshan 2008)  
 
23 
 
 
By 2006 there were over 20 different ARVs available for the management of 
HIV/AIDS (Chao et al. 2006). Table 2.3 below shows the commonly available ARVs 
in the public sector, and the year in which they were launched for the first time in 
developed countries. 
 
Table 2.3: Licensed antiretroviral drugs in South Africa 
Name Launched 
Nucleotide or nucleoside reverse transcriptase inhibitors 
Zidovudine  
Didanosine 
Stavudine 
Lamivudine 
Abacavir 
1987 
1991 
1992 
1995 
1998 
Nucleotide inhibitors 
Tenofovir 
Emtricitabine 
2001 
2003 
Non-nucleoside reverse transcriptase inhibitors  
Nevirapine 
Efavirenz 
1996 
1998 
Protease inhibitors 
Ritonavir 
Lopinavir+ Ritonavir 
1996 
2000 
(Adapted from Department of Health 2010 and Flexner 2007) 
 
The primary goals of ARV therapy are to: 
• Reduce HIV-related morbidity and mortality 
• Improve quality of life 
• Prevent the development of opportunistic infections 
• Suppress viral replication to undetectable levels 
• Restore and preserve immunologic function 
• Prevent vertical HIV transmission  
(Aid for AIDS 2007 and Anderson et al. 2008) 
These goals are made possible due to the availability of a wide variety of ARVs, 
which have the ability to target various stages of the HIV replication cycle. Figure 2.4 
below shows the various stages at which antiretroviral action takes place. As will be 
noted in the discussion below, side effects of ARVs may affect the general wellbeing 
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of the patient, and may be one of the reasons for concomitant use of TCAMs. 
However, with concomitant use, metabolism of ARVs may be affected, and 
therapeutic levels may be altered to toxic or sub-therapeutic levels. Sub-therapeutic 
levels may further potentiate the development of viral resistance to these drugs. 
 
Figure 2.4: Sites of antiretroviral action (Source: Volberding et al. 2009) 
 
i. Reverse transcriptase inhibitors 
This class of drugs inhibits the transcription process (Refer Figure 2.4: Stage 
2), which is vital for HIV replication, by inhibiting the viral reverse transcriptase 
enzyme. 
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a) Nucleotide reverse transcriptase inhibitors (NRTIs) 
NRTIs are active against both HIV-1 as well as HIV-2. The drug undergoes 
intracytoplasmic activation as a result of enzymatic phosphorylation to the 
triphosphate form. The activated form of the drug is then able to 
competitively inhibit HIV reverse transcriptase and may also undergo 
incorporation into viral DNA to cause chain termination. (Safrin 2004) 
(Refer Figure 2.2 and Figure 2.4)  
• Zidovudine 
Zidovudine is well absorbed from the gut, following oral administration, 
and distributed to most body tissues and fluids. In the cerebrospinal 
fluid, the drug reaches up to 60-65% of serum levels. Plasma protein 
binding is approximately 35%. Elimination occurs renaly following 
glucuronidation by the liver. (Safrin 2004) 
Clinical studies have shown zidovudine to be effective in decreasing 
the rate of disease progression and prolonging survival in HIV positive 
patients. It has been shown to be effective in the treatment of HIV-
associated dementia and thrombocytopenia, and reduces vertical 
transmission of HIV from mother to child during birth by up to 23%. 
(Safrin 2004) 
The development of resistance to zidovudine may reduce its clinical 
efficacy. Resistance to the drug is seen in strains with three or more of 
the five most common mutations namely, M41L, D67N, K70R, T215F 
and K219Q. Resistance may occur as a result of non-adherence to the 
medication by the infected individual, or the concomitant use of agents 
that reduce its clinical efficacy. However, the development of 
resistance to the drug may increase the susceptibility of the resistant 
viral strain to other ARVs, and therefore switching to other ARVs may 
facilitate elimination of these strains. (Safrin 2004) 
Myelosuppresion is the most common adverse effect of zidovudine, 
resulting in macrocytic anaemia and neutropenia.  Gastrointestinal 
intolerance, headache and insomnia may also occur upon initiation of 
therapy, but resolves over time. Lactic acidosis, myopathy, seizures, 
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confusion, mania and hepatotoxicity have been reported.  Higher 
serum levels of zidovudine, as may occur due to drug-induced 
inhibition of first-pass metabolism or elimination of the drug, may result 
in anxiety, confusion and tremulousness. (Anderson et al. 2008 and 
Safrin 2004) 
• Didanosine 
Didanosine is inactivated at acid pH and absorption may be reduced 
significantly if ingested within 2 hours of a meal. Cerebrospinal fluid 
concentrations of the drug are approximately 20% that of serum 
concentrations. The drug is eliminated via glomerular filtration and 
tubular secretion. (Safrin 2004) 
Resistance to didanosine may occur as a result of mutation at codon 
74, which may further result in cross-resistance with abacavir, 
zalcitabine and lamivudine. However resistance at this codon may also 
cause a restoration of susceptibility to zidovudine. (Safrin 2004) 
Adverse effects associated with didanosine include nausea, painful 
peripheral distal neuropathy, lactic acidosis, diarrhoea, hepatitis, 
oesophageal ulceration, cardiomyopathy, and central nervous system 
toxicity. Didanosine therapy may also result in a dose-dependent 
pancreatitis. (Anderson et al. 2008 and Safrin 2004) 
• Stavudine 
Stavudine has high oral bioavailability which is independent of food 
intake. The cerebrospinal fluid concentrations are 55% that of plasma 
concentrations. Plasma protein binding is minimal, and elimination of 
the drug is via tubular secretion and glomerular filtration. (Safrin 2004) 
The V75T and 150T viral mutants have a decreased susceptibility to 
stavudine, with V75T having a further reduced susceptibility to 
didanosine and zalcitabine. Clinically significant resistance to stavudine 
is rare. Combining ARVs with stavudine would be necessary in order to 
effectively eliminate the viral strains and prevent generation of new 
mutant strains. (Safrin 2004) 
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Adverse effects associated with stavudine include pancreatitis, 
arthralgias, lipodystrophy, lactic acidosis, gastrointestinal intolerance, 
hyperlactatemia, hyperlipidemia and dose-related peripheral sensory 
neuropathy. (Anderson et al. 2008 and Safrin 2004) 
• Lamivudine 
Oral bioavailability of lamivudine exceeds 80% and is independent of 
food intake. Protein binding is less than 36% with most of the drug 
being eliminated unchanged in the urine. (Safrin 2004) 
Lamivudine has synergistic activity in combination with a variety of 
ARV nucleoside analogs including zidovudine and stavudine. It has 
activity against both zidovudine-sensitive and zidovudine-resistant viral 
strains. (Safrin 2004) 
The M184V mutants of HIV show a high level of resistance to 
lamivudine and a reduced susceptibility to abacavir, didanosine and 
zalcitabine. Lamivudine is therefore best used as combination therapy 
with ARVs that are fully suppressive of viral replication to reduce the 
generation of viral mutants. The M184V mutants are susceptible to 
zidovudine, indicating a rational combination of the two drugs for 
effective elimination of the virus. (Safrin 2004) 
Side effects associated with lamivudine are typically mild and include 
headache, insomnia, fatigue and gastrointestinal discomfort. (Anderson 
et al. 2008 and Safrin 2004) 
 
b) Nucleotide Inhibitors 
• Tenofovir 
Nucleotide inhibitors, such as tenofovir, are similar to NRTIs in that 
they inhibit HIV reverse transcriptase and cause chain termination, 
following incorporation into DNA. (Safrin 2004) 
Oral bioavailability of the drug is only 25% following intake in a fasting 
state.  Bioavailability is increased by up to 40% following ingestion of 
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the drug with a high-fat meal. Elimination of the drug occurs as a result 
of glomerular filtration and active tubular secretion. (Safrin 2004) 
Tenofovir, as for the NRTIs, is indicated for use in combination with 
other ARVs. It has been shown to cause potent viral suppression in 
treatment experienced patients. Tenofovir is dosed once daily thereby 
improving adherence to the medication.  (Safrin 2004) 
Cross-resistance to tenofovir may occur with pre-existing zidovudine-
associated mutations. The presence of 65R mutations also decreases 
virologic response. However, cross-resistance with lamivudine-
abacavir-associated M184V mutations as well as with protease 
inhibitors does not occur.  (Safrin 2004) 
Adverse effects associated with tenofovir include nausea, vomiting, 
diarrhoea and flatulence. Renal insufficiency, Fanconi Syndrome and 
osteopenia may also occur. (Anderson et al. 2008 and Safrin 2004) 
 
c) Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
This class of drugs exert their activity by binding directly to a site on the 
viral reverse transcriptase enzyme, resulting in the inhibition of the RNA- 
and DNA-dependant DNA polymerase activities. The binding site of the 
NNRTIs is distinct from that of the NRTIs. The generation of resistant viral 
strains may occur rapidly during monotherapy, and though cross-
resistance does occur, this occurrence is of little clinical significance. 
(Safrin 2004) 
  
• Nevirapine 
Nevirapine has oral bioavailability of over 90% which is independent of 
food intake. Approximately 60% of the drug is protein bound and 
cerebrospinal fluid concentrations are 45% of plasma levels. 
Nevirapine is extensively metabolised by the hepatic CYP3A4 enzymes 
and is excreted in the urine. It is also an inducer of the CYP3A 
metabolism. Nevirapine should therefore be used with caution, if at all, 
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with agents which are substrates of the CYP3A enzymes or which 
potentially induce or inhibit these enzymes. (Safrin 2004) 
Nevirapine has been shown to prevent transmission of the virus from 
mother to child during childbirth. It effectively suppresses viral 
replication when used in combination with other ARVs. (Safrin 2004) 
Adverse effects associated with the use of nevirapine include fever, 
nausea, headache and somnolence. Severe, life threatening rashes 
may occur in up to 17% of patients in which case the drug should be 
discontinued immediately. Symptomatic hepatitis, including fatal 
hepatic necrosis has also been reported. (Anderson et al. 2008 and 
Safrin 2004) 
 
• Efavirenz 
Efavirenz is moderately well absorbed following oral administration and 
bioavailability is increased with a fatty meal.  It is metabolised mainly 
by the CYP3A4 and CYP2B6 hepatic enzymes to the inactive 
hydoxylated metabolites. Up to 99% of the drug is protein bound. 
Cerebrospinal fluid concentrations range from 0.3% to 1.2% of the 
plasma levels. (Safrin 2004) 
Efavirenz is an inhibitor and a moderate inducer of the CYP3A4 
enzymes. It therefore potentially induces its own metabolism, and 
interacts with many agents, including TCAMs, that are metabolised by 
these enzymes. Agents which are capable of inducing CYP3A4 
enzymes may increase the metabolism of efavirenz, potentially 
reducing it to sub-therapeutic levels. (Safrin 2004) 
Adverse effects associated with efavirenz include dizziness, 
drowsiness, insomnia, headache, confusion, amnesia, delusions, 
depression, nightmares and euphoria. These adverse effects usually 
occur on initiation of therapy and resolve with time. Other adverse 
effects include rash, nausea, vomiting, crystalluria, elevation of liver 
enzymes and increase in the total serum cholesterol. Efavirenz has 
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been shown to be teratogenic and therefore should be avoided in 
pregnancy. (Anderson et al. 2008 and Safrin 2004) 
 
ii. Protease inhibitors 
During the replication cycle, long protein chains are synthesised by the viral 
RNA and cleaved by the protease enzyme to produce the final structural 
proteins of the mature virion (Refer Figure 2.4: stage 4 and Figure 2.2). 
Protease inhibitors block activity of the protease enzyme, thereby causing the 
production of immature, non-infectious viral particles. Although potent, 
monotherapy with protease inhibitors is contraindicated as specific genotypic 
alterations that confer phenotypic resistance is fairly common. (Safrin 2004) 
 
Although a subject of controversy, certain abnormalities appear to be 
particularly associated with the use of protease inhibitors. These 
abnormalities include redistribution and accumulation of fat which causes 
central obesity, buffalo hump, peripheral and facial wasting, breast 
enlargement and a cushingoid appearance. Increases in triglyceride and LDL 
levels as well as glucose intolerance and insulin intolerance have also been 
reported. (Safrin 2004) 
 
Protease inhibitors are inhibitors and substrates of the CYP3A4 coenzymes. 
Agents which are metabolised by these enzymes should therefore not be 
used concurrently with protease inhibitors. Agents, including TCAMs, affecting 
the CYP3A4 activity should be used with caution as, given their effect on the 
enzymes, can potentially cause drug levels to go into sub-therapeutic or toxic 
levels. (Safrin 2004) 
 
• Ritonavir  
Both HIV-1 and HIV-2 are inhibited by ritonavir. Resistance to the drug 
occurs due to mutations at positions 84, 82, 71, 63 and 46, of which the 
184V mutation appears to be most critical. (Safrin 2004) 
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Most common adverse effects associated with ritonavir use include 
gastrointestinal disturbances, paresthesias, elevated serum 
aminotransferase levels, altered taste, hepatitis, hyperglycemia and 
hypertriglycerdemia. Nausea, vomiting and abdominal pain usually 
occurs on initiation of therapy and subsides over a few weeks. 
(Anderson et al. 2008 and Safrin 2004) 
 
• Lopinavir/Ritonavir 
Lopinavir and ritonavir, when administered together, have been shown 
to enhance antiretroviral efficacy and improve tolerability. Ritonavir is 
given in sub-therapeutic doses in order to inhibit CYP3A metabolism of 
Lopinavir, thereby increasing exposure to Lopinavir. Lopinavir in 
combination therefore maintains potent viral suppression and creates a 
barrier against the emergence of resistance. (Safrin 2004) 
The most common adverse effects associated with lopinavir/ritonavir 
combination include GI intolerance, nausea, vomiting, diarrhoea and 
asthenia. Hyperlipidemia, elevation of serum transaminases, 
hyperglycemia and fat maldistribution may also occur. (Anderson et al. 
2008 and Safrin 2004) Agents that are highly dependent on CYP3A 
metabolism may undergo interactions with the drug, thereby affecting 
its therapeutic levels. Herbal agents such as Hypericum perforatum (St 
John’s wort) may reduce levels of lopinavir, decreasing its potency and 
making it more susceptible to resistance. (Safrin 2004) 
 
iii. Entry inhibitors 
This class of drugs inhibit entry of the virus into a host cell (Refer Figure 2.4: 
stage 1) 
• Enfuvirtide 
Enfuvirtide, also known as a fusion inhibitor, binds to the gp41 subunit 
of the viral glycoprotein (Refer Figure 2.1), thereby preventing the 
conformational changes required for the fusion of the viral and cellular 
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membranes.  Resistance to enfuvirtide can occur, however, owing to its 
distinct site of action, cross resistance with other drugs is unlikely. 
(Safrin 2004) 
In order to combat resistant viral strains, treatment-experienced 
patients undergoing persistent viral replication despite ongoing ARV 
therapy, may be initiated on subcutaneous enfuvirtide in combination 
with other ARVs. The drug shows up to 92% protein binding and 
metabolism is by proteolytic hydrolysis, without the involvement of 
CYP450 enzymes. (Safrin 2004) 
Adverse effects associated with the use of enfuvirtide include local 
injection site reactions, increased bacterial pneumonia, hypersensitivity 
reactions of varying severity and eosinophilia. (Anderson et al. 2008 
and Safrin 2004) 
 
• Maraviroc 
Maraviroc binds to the CCR5 co-receptor on the CD4 cell (Refer Figure 
2.1) causing a conformational change which inhibits HIV attachment 
and prevents the process of fusion and entry of the virus into the cell. 
This drug therefore belongs to the class of drugs known as CCR5 
antagonists. (Clax et al. 2007) 
Because maraviroc acts on the host protein rather than the viral protein, 
the virus is unable to prevent the binding of the drug to the CCR5 
receptor. However, it may be able to mutate in such a way as to allow 
binding of the virus to the drug-receptor complex. Due to its distinct site 
of action, cross resistance with other ARVs is unlikely. (Westby 2007) 
Maraviroc may be used in combination with other ARVs for treatment-
experienced patients with persistent viral replication despite ongoing 
ARV therapy. The active form of the drug is a substrate of the CYP3A 
enzymes and therefore, concomitant administration of agents, such as 
TCAMs, with CYP3A inducing or inhibiting potential, should be done 
with caution. Use of herbal remedies such as Hypericum perforatum (St. 
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John’s Wort) with maraviroc is not recommended. (Volberding et al. 
2009) 
Adverse effects associated with maraviroc use include cough, pyrexia, 
rash, muscle and joint pain, GI disturbances and dizziness. Liver toxicity 
may occur in rare cases and, due to the presence of CCR5 receptors on 
some immune system cells there is a theoretical risk of developing 
infections and cancers. (Volberding et al. 2009) 
 
iv. Integrase inhibitors 
This class of drugs targets the process of integration which is vital for viral 
replication (Refer Figure 2.4: Stage 3). 
• Raltegravir 
HIV integrase is an essential enzyme that catalyzes insertion of viral 
DNA into the host’s cell genome. This process is required for viral gene 
expression and replication. Raltegravir inhibits the process of 
integration by inhibiting integrase activity thereby blocking the 
replication cycle. (Omar and Cahn 2007) 
The major mechanism of clearance of raltegravir is via glucuronidation. 
It is not a substrate of the CYP450 system, neither does it have an 
inhibiting or inducing effect on these enzymes. This implies an absence 
of interactions with agents metabolised by this system. (Omar and 
Cahn 2007) 
Due to its distinct therapeutic target, raltegravir is expected to maintain 
its activity against viral strains resistant to other classes of ARVs. As 
combination therapy, raltegravir has a “rapid, potent, and sustained 
antiretroviral effect” in treatment-experienced patients with persistent 
viral replication. (Grinsztejn et al. 2007) It is capable of achieving 
virological suppression even in patients with limited options (Omar and 
Cahn 2007). 
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Raltegravir is generally well tolerated. Common adverse effects include 
diarrhoea, nausea, headache and pyrexia. Long term adverse effects 
of raltegravir have not been reported. (Omar and Cahn 2007) 
 
2.5. STANDARD PRACTICE 
The National Department of Health’s recommended regimens for ARV therapy, as of 
the year 2010, are as follows:  
 
• Regimen 1a: Tenofovir + Lamivudine or Emtricitabine + Efavirenz or 
Nevirapine 
• Regimen 1b: Stavudine + Lamivudine + Efavirenz or Nevirapine 
• Regimen 1c: Zidovudine + Lamivudine + Efavirenz or Nevirapine 
• Regimen 2a: Tenofovir + Lamivudine or Emtricitabine + 
Lopinavir/Ritonavir 
• Regimen 2b: Zidovudine + Lamivudine + Lopinavir/Ritonavir 
 
However, data collection for this study was carried out in 2009, during which time the 
2004 guidelines were still being implemented. The Department of Health’s (2004) 
recommended first line regimens for ARV therapy included: 
 
• Regimen 1a: Stavudine/Lamivudine/Efavirenz 
• Regimen 1b: Stavudine/Lamivudine/Nevirapine 
• Regimen 1c: Zidovudine/Lamivudine/Efavirenz or Nevirapine 
• Regimen 1d: Tenofovir/Lamivudine/Efavirenz or Nevirapine 
 
Unless contraindicated, all patients eligible for ARV treatment were initiated on 
regimen 1a. Efavirenz is contraindicated in the first trimester of pregnancy, in 
patients who are on psycho active drugs and patients not using effective 
contraception. Stavudine is contraindicated in patients with symptoms of pre-existing 
neuropathy, patients with a history of severe stavudine toxicity and in female patients 
with a BMI > 28. The use of regimen 1a is also contraindicated in patients who tested 
positive for Hepatitis B. (Department of Health 2004) 
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If efavirenz from regimen 1a was contraindicated, it was substituted with nevirapine 
(regimen 1b). Nevirapine is contraindicated in patients with ALT levels elevated to 
five times the upper limit of normal. It should also not be used with rifampicin during 
TB treatment. (Department of Health 2008) 
 
Regimen 1c was recommended for female patients with a BMI of >28 and in patients 
susceptible to stavudine toxicity. However, zidovudine is contraindicated in patients 
with haemoglobin levels below 6.5g/dl or when neutrophil count is below 0.5 x 109 /l, 
especially if the patient is also on cotrimoxazole. (Department of Health 2008) 
 
Regimen 1d was recommended for patients who experienced stavudine toxicity and 
those with a positive Hepatitis B Ag serology test.  Tenofovir is however 
contraindicated in patients with a GFR or creatinine clearance <50ml/min. 
(Department of Health 2008)     
 
Patients unable to suppress their viral load in spite of a good adherence record were 
initiated on second line ARV regimens. These regimens included: 
 
• Regimen 2a: Zidovudine/Didanosine/Lopinavir/ritonavir 
All patients with virological failure on regimen 1 were initiated on regimen 2a, 
unless contraindicated.    
 
• Regimen 2b: Tenofovir/Lamivudine/Lopinavir/ritonavir 
This regimen was recommended for patients who had developed severe 
toxicity to stavudine.   
 
• Regimen 2c: Zidovudine/Didanosine and double dose Lopinavir/ ritonavir 
This regimen was recommended for patients using rifampicin while on TB 
treatment. 
 
Side effects of ARVs, drug toxicity and resistance concerns coupled with the cost of 
medications for large-scale public health programmes are factors considered in 
determining HAART initiation criteria (Warlick 2008). According to the National 
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Department of Health (2004) ARV rollout programme, patients received ARV therapy 
if they met the following criteria: 
 
 The patient was prepared and willing to comply with taking antiretroviral drugs 
correctly as prescribed; and  
 The patient had a WHO stage 4 AIDS defining illness, irrespective of CD4 
count; or 
 a CD4 count of less than 350 cells/mm3 and a WHO stage 3 condition; or 
 A CD4 count less than 200 cells/mm3 and/or symptomatic of AIDS, 
irrespective of stage. 
(Aid for AIDS 2007: 32; Department of Health 2008) 
 
The 2004 Department of Health guidelines recommended a CD4 threshold of 200 
cells/mm3. Although a proposition was made to raise the CD4 threshold to 250 
cells/mm3 (Department of Health 2008), the newer (2010) guidelines still recommend 
initiating ARVs at 200 cells/mm3. Recent studies however associate initiation of 
HAART at a CD4 count of 350 cells/mm3 with lower mortality, faster immune 
recovery, and less drug-related toxicity and adverse side-effects (Warlick 2008). 
 
The HIV outpatient study (HOPS), for example, showed abnormal fat loss occurring 
in 30.8% of patients initiated on HAART at a CD4 count of 200 cells/mm3, while only 
3.3% experienced this side effect at 350cells/mm3 (Lichtenstein et al. 2003). The 
incidence of peripheral neuropathy has also been shown to be higher in patients 
when therapy is initiated at lower CD4 counts (Simpson et al. 2002). A randomised 
study in Cote D’Ivoire showed significantly improved treatment outcomes and much 
reduced mortality and morbidity in patients initiating therapy above a CD4 count of 
350 cells/mm3 (Moh et al. 2007). The mortality rate in patients initiating therapy at a 
CD4 range of 350-500 cells/mm3 was shown to be approximately 60% of those 
initiated at a CD4 count of less than 350 cells/mm3 (Palella et al. 2003). Also, the 
Strategies for the Management of Antiretroviral Therapy (SMART) trials show a 
higher occurrence of HIV/AIDS related illnesses and non-AIDS defining health 
conditions in untreated-HIV, below a CD4 count of 350 cells/mm3 (Warlick 2008). 
Sexual transmission has also been shown to be reduced when HAART is initiated at 
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an early stage (Quinn et al. 2000) and therefore possibly an efficient and cost 
effective intervention for preventing new HIV infections (Badri et al. 2004).  
 
2.6. Perception of therapeutic outcome 
The effectiveness of recommended conventional allopathic medicines including 
ARVs has been proven to be beneficial in HIV-positive patients. However, the 
efficacy of the medication in ideal situations and the effectiveness in real life 
situations usually differs (Buckalew 2006). In ideal situations, patients use the correct 
medication appropriately in order to prevent, cure or ameliorate disease symptoms. 
However, in real life circumstances, patient understanding and perception of the 
disease and treatment may play a major role in adherence to appropriate medication 
(Buckalew 2006). Perception is important as individual behaviour is based on their 
perception of what reality is, and not on reality itself. The world that is perceived is 
the world that is behaviourally important (Robbins et al. 2003). Depending on the 
level of education, individual perception is usually driven by religion (Colzato et al. 
2008), culture and tradition (Nauert 2007). With perceptual engineering it may be 
possible to enhance adherence to medication (Buckalew 2006). With the majority of 
the HIV-positive population being inadequately educated, it would be important to 
understand patient perception, including perceived benefits and threats towards the 
disease and treatment, in order to be able to devise a systematic counselling plan for 
a better therapeutic outcome. 
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Chapter 3 
HIV MANAGEMENT: NON-CONVENTIONAL 
 
3.1. TRADITIONAL, COMPLEMENTARY AND ALTERNATIVE MEDICINE 
Traditional, complementary and alternative (TCAM) therapies have been around for 
hundreds of years and are the primary source of healthcare for over 70% of the 
world’s population (Ernst et al. 2001). “Traditional medicine is the sum total of 
knowledge, skills and practices based on the theories, beliefs and experiences 
indigenous to different cultures that are used to maintain health, as well as to 
prevent, diagnose, improve or treat physical and mental illnesses. Traditional 
medicine that has been adopted by other populations (outside its indigenous culture) 
is termed alternative or complementary medicine.” (WHO 2008) Traditional 
medicines can therefore also be regarded as a type of complementary or alternative 
medicine.  
 
An investigation carried out by Peltzer and colleagues in 2008, explored the use of 
traditional, complementary and alternative medicines (TCAMs) in HIV-positive 
patients in Kwazulu Natal.  The aim of the cross-sectional study was to assess the 
use of TCAMs by HIV-positive patients prior to the initiation of ARVs. The 
investigation was carried out by using systematic sampling, in which 618 HIV-
positive patients were selected from the outpatient departments at three hospitals 
and interviewed with a questionnaire. The results indicated that TCAMs were 
commonly used by 51.3% (n=618) of the participants, of which 29.6% (n=618) used 
herbal remedies. Herbal remedies were the most expensive, costing an average of 
R128 per patient per month. Of the 317 participants that used TCAMs, 90% 
indicated that their Health Care Provider was unaware of their use of TCAMs for the 
treatment of HIV. Another investigation carried out in 2008, by Ladenheim and 
colleagues, exploring the potential health risks of complementary and alternative 
medicine (CAM) in HIV-positive patients in Central London, United Kingdom, showed 
that, out of a total of 293 patients, 61% were taking herbal remedies, 35% were 
using physical treatments while 27% used a combination of both. Of the patients who 
were undergoing HIV treatment, 20% potentially compromised their treatment by 
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using CAM therapy, 10% were advised to discontinue it and 15% were made aware 
of potential drug interactions and adverse effects associated with the CAM they were 
on. 
 
A preliminary study carried out by Lunat (2008), investigating the extent to which 
herbal remedies are prescribed to HIV-positive patients in the Eastern Cape, showed 
that the majority of HCPs who participated in the study believed their patients were 
using some type of traditional, complimentary or alternative medicine that was not 
disclosed by patients to HCPs. Patients are usually discouraged by HCPs to use 
traditional or herbal medicines during ARV therapy. However, according to the study, 
patients, due to their cultural and traditional backgrounds tend to ignore advice which 
does not correspond with their beliefs and do not reveal the true use of TCAM during 
counselling.  
 
There were approximately 200 000 African traditional healers in South Africa in 2003 
(Dickinson 2008) compared with 25 000 certified doctors (Ndhlala 2009). The WHO, 
in 2002, estimated almost 80% of the African population to be making use of the 
services offered by traditional healers. With the majority of the population making 
use of traditional healers, and a limited number of HCPs, close collaboration of the 
two parties would be helpful in the fight against HIV. (Dickinson 2008)  
 
Some traditional medicines, such as Sutherlandia and Lobostemon, have been 
commercialised in South Africa, making them more easily accessible to populations 
outside the indigenous culture. These medicines may therefore also be regarded as 
complementary or alternative in the context of other cultures, within the same 
country. There are also numerous complementary and alternative medicines, 
traditional to other geographic regions and cultures, such as Chinese medicines, 
available on the South African market.  
 
3.1.1. Traditional medicine 
“African traditional medicine is characterized by a holistic approach to the spirit-mind-
body concept of health, embracing people, animals, plants and inanimate objects in 
an inseparable whole from which all beings derive their living and healing forces” 
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(Homsy et al 2004). Traditional healing is much more holistic in its approach to the 
patient, compared with conventional medicine practice (Dickinson 2008). 
 
Most African traditional healers combine the practice of ‘divination’ and ‘treatment’, 
though some, referred to as herbalists, practice ‘treatment’ alone. Divination 
comprises the practicing of certain rituals such as the ‘throwing of bones,’ and 
treatment being the use of medicines such as herbal remedies. Overall, treatment 
involves herbal medication, advice and coaching on a wide range of problems, 
emotional empathy, rituals to allow patients to communicate with ancestors, 
protection against witches, and holding cultural events that may have been 
neglected. (Dickinson 2008) 
 
In South Africa, individuals get an ancestral ‘calling’ towards traditional healing after 
which they locate a traditional healer who will act as their teacher. Knowledge of 
traditional healers is therefore passed on from teacher to student. The traditional 
healing courses usually last about a year, with additional months for those seeking to 
become herbalists. As the students become teachers, a vertical clan-like structure is 
created and knowledge is shared amongst the clan. Furthermore, the network of 
traditional healers is extended via communication between separate clans living in 
close proximity. Over three to five years, a single traditional healer may come in 
contact with as many as 400 other traditional healers. These networks create 
structures of contact, referral, knowledge, and ethical standards within traditional 
healing. (Dickinson 2008)  
 
In Africa, traditional healing dates back hundreds of years. The introduction of the 
more recent religions, such as Christianity, acts as a rival and competitor over the 
construction of meaning. Individuals seek to practice religion without having to forego 
family cultures and traditions, making the relationship between religion and 
traditions, a complex one. Some individuals practice religion openly, with traditional 
beliefs in hiding, in direct defiance of the church. However, a growing number of 
African churches are synchronizing traditional beliefs, with parallel healing practices. 
(Dickinson 2008) 
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Secondary to religion, comes the introduction of western medicines into the African 
setting. Although synchronization between religion and traditions has been found to 
be possible, a similar parallel may be difficult to achieve with western medicines. The 
majority of HCPs refuse to acknowledge any role of traditional healing as a legitimate 
health care system. HCPs seek transparency as far as treatment is concerned, 
whilst traditional healers, for fear of having treatments stolen from them, closely 
guard their herbal treatments as property of individual clans. Many traditional healers 
also fear the subservient position, making them reluctant to work with HCPs. 
(Dickinson 2008) 
 
“Essentially, traditional healing and western medicine represent two rival healing 
systems in which the latter dominates publicly through an alliance with the state and 
employers, while the former privately retains considerable sway within large sections 
of the population”. (Dickinson 2008) 
 
TCAM agents that are available in South Africa and are commonly used for 
medicinal purposes to combat HIV will be discussed below. 
 
3.1.2. Sutherlandia 
Sutherlandia is also known as “insisa”, the “one that dispels darkness”. The San 
people of Southern Africa have used this species of plant for centuries as an “energy 
booster” and a powerful “anti-depressant”. Zulu sangomas or traditional healers 
know Sutherlandia as “unwele”, the great medicine that was believed to ward off the 
effects of the devastating 1918 influenza pandemic which claimed many lives 
worldwide. The Tswana people know it as “mukakana” for its power in treating 
gonorrhoea and syphilis, while the Afrikaners call it the “kankerbossie” or cancer 
bush, because of its properties in treating people suffering with internal cancers and 
wasting. (Dempster 2001) 
Sutherlandia is an attractive, small, soft wooded shrublet, 0.5 to 1 metre in height. 
The leaflets are 4-10 mm long, grey-green in colour, giving the bush a silvery 
appearance. The flowers are orange-red, up to 35 mm long, and are carried in short 
racemes in the leaf axils at the tips of the branches in spring to mid-summer 
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(September – December). The fruit is a large, bladder-like, inflated pod and is almost 
transparent. (Notten and Xaba 2008)  
 
 
Figure 3.1: Sutherlandia frutescens (Source: McGreggor 2008) 
 
The principal constituents of Sutherlandia frutescens that are purported to be active 
include L-canavanine, GABA, and D-pinitol. L-canavanine is a non-protein amino 
acid that is the L-2-amino-4-guanidinooxy structural analogue of L-arginine. There is 
about 30–40 mg of L-canavanine per dry gram of the Sutherlandia frutescens leaf. 
D-pinitol is a type of sugar found in many types of legumes and is classified as a 
chiro-inositol. GABA (gamma-amino butyric acid) is both an amino acid and inhibitory 
neurotransmitter. It is found at levels of 14 mg per gram of dry S. frutescens leaf. 
(Gericke et al. 2001) 
 
Sutherlandia has been shown to produce near complete inhibition of CYP3A4 (96%) 
and P-glycoprotein expression (Mills et al. 2005). “In spite of the relatively high 
concentrations used in the in vitro experiments, the results tentatively suggest that 
human consumption of Sutherlandia could affect anti-retroviral drug metabolism 
leading to bi-directional drug interactionsW” (Mills et al. 2005).  In vivo human 
studies are required to determine if there is a clinically relevant drug/herb interaction 
and if so, to identify the true extent of the interaction.  
Anecdotal evidence, such as that of Anne Hutchings, an ethno-botanist and lecturer 
at the University of Zululand, cited by Dempster (2001), suggests that Sutherlandia 
together with a range of other indigenous plant medicines, when used to treat AIDS 
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patients who attended the weekly AIDS clinic at the Ngwelezane Hospital, helped 
give all 176 patients a fuller, healthier and more productive life. 
In vitro studies, such as those carried out at Nelson Mandela Metropolitan University 
(NMMU) in 2004, have shown Sutherlandia to have inhibitory properties against HIV 
target enzymes, thus showing a potential mechanistic action of these plants in aiding 
HIV-positive patients (Harnett 2004). Although much work has been done on 
Sutherlandia, besides the anecdotal evidence, there is no substantial published in 
vivo evidence that identifies how Sutherlandia may be helping AIDS patients, or 
supports the suggestion that it is doing so. 
 
3.1.3. Lobostemon 
Lobostemon fruticosus is also known in Afrikaans as “ag dae genees bos”, meaning 
the eight-day healing bush, due to its apparent ability to heal a condition in eight 
days. Another name used is “douwurmbos”, as it is believed to treat ringworms. 
Decoctions of Lobostemon fruticosus are used to treat wounds, skin disease, 
ringworm and ulcers while infusions are used for general internal problems and to 
“purify the blood”. (Harnett 2004) 
 
Lobostemon is a shrub with hairy branches and is a mottled pink colour when young. 
The leaves are leathery and the flowers are clustered at the end of its branches. The 
flowers are funnel shaped, pink or blue suffused with pink. The fresh leaves and 
twigs of this plant are used medicinally. (Shwegler 2008) 
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Figure 3.2: Lobostemon (Source: Penny 2008) 
 
Lobostemon fruticosus is closely related to comfrey (Symphytum officinale) and 
borage (Borago officinales). For this reason it is thought that Lobostemon fruticosus 
may have similar compounds (Harnett 2004). Comfrey contains allantoin, which is 
well known for its wound-healing properties. Comfrey also contains pyrrolizidine 
alkaloids like symphytine but this is a cumulative toxin (Van Wyk et al. 2000). 
 
In vitro studies carried out at the NMMU have shown Lobostemon leaf extracts to 
have a potent HIV-1 Reverse Transcriptase inhibitory effect, thus suggesting a 
potential mechanistic action of these plants in aiding HIV-positive patients (Harnett 
2004). Traditional healers also believe this plant to have anti-HIV properties. 
However, besides the in vitro investigations and the anecdotal evidence, there is no 
substantial published evidence that identifies the in vivo effect of Lobostemon in 
aiding HIV/AIDS patients.  
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3.1.4. Hypoxis hemerocallidea 
Hypoxis hemerocallidea (or H. rooperi) is also known locally in South Africa as magic 
muthi, yellow stars, star lily and African potato. In Afrikaans it is known as sterretjie, 
Afrika-patat and in local indigenous languages it is referred to as inkomfe, 
ilabatheka, sterblom, gifbol, lotsane and molikharatsa (Mills et al. 2005). 
The name Hypoxis comes from the Greek words hypo meaning below and oxy 
referring to the pointed base of the ovary or fruit. The Hypoxis plant is easily 
recognizable by its bright yellow star-shaped flowers and strap-like leaves. It has 2-
12 flowers per stalk which are symmetrical with 6 petals. The fruit is a capsule that 
splits across its diameter to expose the small black seeds. The leaves of the Hypoxis 
plant are arranged one above the other in three rows that radiate outwards and 
range from broadly lance shaped to linear. They wither over the winter months and a 
new set of leaves grow from the apex of the bulb, with flowering stems after the first 
rains in spring. (Singh 2004) 
 
Figure 3.3: Hypoxis hemerocallidea (Source: Hornig 2008) 
Hypoxis has a long history of medicinal use on the African continent. The rootstocks 
of this plant have been used by Zulu traditional healers in the treatment of urinary 
tract infections, heart weakness, internal tumours, nervous disorders, benign 
prostatic hypertrophy, cancer and hyperglycemia.  The bulbs of H. hemerocallidea 
are used for immune related illnesses such as the common cold, flu, arthritis, cancer 
and HIV/AIDS. (Mills et al. 2005) There is some indirect evidence that sterols and 
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sterolins, which are found in the root of Hypoxis, have the potential to enhance 
immunity (Muwanga 2006). 
An important constituent of the plant is a nor-lignan glycoside called hypoxoside, 
which is readily converted to a potent antioxidant aglycone, rooperol, in the human 
gut. Conversion of hypoxoside to rooperol is mediated by beta-glucosidase, an 
enzyme found predominantly in the gastrointestinal tract. Phase I biotransformation 
of both Hypoxoside and rooperol occurs via the P450 system and most likely by the 
CYP 3A4 enzymes. (Mills et al. 2005) Rooperol is a biologically active compound 
that is purported to have immune boosting properties. Hypoxis also contains various 
sterols including β-sitosterol and stigmasterol, sterolins such as β-sitosterol 
glycoside and stanols such as sitostanol. These constituents have also been 
purported to have important biological activity including stimulation of the immune 
system. (Muwanga 2006) 
In vitro investigation of Hypoxis shows inhibition of normal CYP3A4 isoform activity 
by up to 86% (Mills et al. 2005).  The herb can therefore potentially interact with HIV 
drug metabolising enzymes, which could subsequently lead to drug toxicity and 
treatment failure. A study on the safety and efficacy of the Hypoxis plant extract in 
HIV-positive patients was terminated prematurely by the Data and Safety Monitoring 
Committee, and reported to the Medicines Control Council, because most of the 
patients who received the extract showed severe bone marrow suppression after 
eight weeks. Also of great concern is the suspicion of Hypoxis-induced immune 
suppression in feline AIDS. In a study cited by Terreblanche (2003), the cats in the 
investigation progressed and succumbed to full-blown AIDS faster than those not 
treated by the Hypoxis extract. 
 
3.1.5. Allium sativum (Garlic) 
The health benefits of Garlic, which is indigenous to Asia, have been exploited for 
thousands of years around the world (Maoela 2005). The oldest available records of 
the use of garlic, written by Sumerians on stone tablets, date back to 2600 BC. 
Another source of Sumerian texts referring to garlic in the year 669 BC is found in 
the library of Assyrian King Assurbanipal. It is also believed to have been used 
during the first Chinese Dynasty during 2205-1766 BC. (Limson 2001) 
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Garlic has linear sheathing leaves with flowers grouped together in a globular head 
or umbel. The bulb, which consists of numerous bulblets or “cloves”, is the only part 
of the plant that is eaten. The cloves are held together between membranous scales 
and enclosed together in a whitish skin. (Grieve 1995) The garlic odour is weak 
when the plant is intact, and grows stronger when damaged (Maoela 2005). 
 
Figure 3.4: Allium sativum flower (Source: Woodward 1996) 
 
 
Figure 3.5: Garlic clove (Source: Phillips 1993) 
 
Garlic extracts have been shown to have antifungal activity against seven species of 
Candida and two species of Cryptococcus found in the human serum (Prasad 1980). 
The main ingredient in garlic which provides health benefit is called allicin (Aucamp 
2008). Allicin also has anti-bacterial properties against various gram positive and 
gram negative bacteria belonging to Staphylococcus, Streptococcus, Bacillus and 
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Vibrio (Singh et al. 2001). Delaha and Garaguci (1985) also showed garlic extract to 
have an inhibitory effect against Mycobacterium tubercolosis. Garlic oil and some of 
its components have been shown to have antioxidant properties by inhibiting 
lipooxygenase, one of the enzymes involved in arachidonic acid metabolism (Block 
1988). Garlic lowers levels of serum cholesterol and triglyceride by inhibiting their 
biosynthesis in the liver (Sumiyoshi 1997). The allicin component of garlic has 
hypocholesterolemic (Aucamp 2008) and antidiabetic (Kumari 1995) properties.  This 
hypocholesterolemic property provides the beneficial activity against artherosclerosis 
and coronary thromobosis (Singh et al. 2001). It may also have an anti-cancer and 
an immunomodulatory effect (Singh et al. 2001). Tatarintsev and colleagues (1992) 
propose administration of ajoene, an ingredient of garlic, with conventional anti-HIV 
drugs due to its apparent inhibitory effect on HIV-mediated syncytia formation.  
 
Experimental data suggests garlic is a substrate, inhibitor and/or inducer of various 
CYP450 enzymes (Stargrove et al. 2007). Simultaneous administration of garlic and 
ritonavir has been reported to cause severe gastrointestinal side effects (Piscitelli et 
al. 2000), and garlic supplements may reduce the concentration of saquinavir by 
over 50%. Saquinivir concentrations may not return to normal even after a 10-day 
wash out period, probably due to a metabolite or component with a long half life and 
enzyme-inducing capabilities (Piscitelli et al. 2002). 
   
3.1.6. Aloe vera 
Aloe vera has been used for thousands of years with records dating back to ancient 
civilizations including Egypt, Greece, Rome, Persia, India and Africa (Tenney 1997). 
Historical evidence suggests the origin of Aloe vera to be in the warm, dry climate of 
Africa (Hedendal 2000). The plant is reported to have numerous health benefits with 
McDaniel (1987) stating, “the use of Aloe vera will be the most important single step 
forward in the treatment of diseases in the history of mankind.”  
 
The Aloe vera plant has thick, succulent, green leaves encircling a thick central 
stem, 30-80cm long. Mature leaves are 2-2.5cm thick and 6-10cm wide at the base, 
thinning and narrowing towards the apex. The margin of the leaf is serrated with firm, 
triangular shaped teeth. The flower stalks develop in summer, from the main stem, 
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on a spike reaching 60-90cm. Each flower is pendulous with a green tinge that 
changes to bright yellow on maturity. (Shipard 2003) 
 
Figure 3.6: Aloe vera (Source: Andéra 2008) 
  
Aloe-emodin, formed in the colon through reductive cleavage of glycosides by 
epithelial or bacterial enzymes, irritates the intestinal mucous membranes, increases 
mucous secretion and stimulates peristalsis. This makes Aloe vera a potent laxative. 
The C-glucosyl component of Aloe vera exhibits a strong anti-inflammatory effect. 
Aloe vera is also used in cosmetics as it possesses re-epithelizing, anti-
erythematous, moisture binding and absorptive properties. (Wichtl 2004) An 
investigation carried out by Galal et al. (1975) showed administration of aloe gel prior 
to ulcer-inducing stress reduced ulcer cases by 80%, and if given after ulcer 
formation, the healing process was three times faster compared to that in the control 
population. Kandil and Gobran (1979) showed a 30% reduction in stomach lesions. 
Studies have also shown a beneficial effect of aloe in coronary heart disease by 
lowering serum cholesterol, serum triglycerides, and phospholipids. According to 
Suzuki (1979), aloe also has anticancer activity against lymphocytic leukaemia. 
(Danhof 2000)  
 
In HIV, the polysaccharide fraction of aloe has antiviral activity and enhances cell 
function (Danhof 2000). Patients treated with the mannose extract of aloe showed a 
decrease in the production rate of HIV-1, and suppression in the spread of viruses 
from infected cells. The extract was also found to stimulate the T4-helper cells of the 
immune system. (Wichtl 2004) An investigation carried out by McDaniel and 
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McAnalley (1988) on eight AIDS patients showed an improvement in symptoms 
within 90 days of therapy with the polysaccharide. Fever, night sweats and diarrhoea 
were reduced with six of the eight patients experiencing a controlled or complete 
elimination of opportunistic infections. The study reported to have a conversion of 
positive cultures to negative in three patients. Clinical toxicity and side-effects were 
entirely absent. However, this study was uncontrolled and further investigations of 
this nature would be necessary to validate the results. (Danhof 2000) 
 
Concomitant administration of aloe gel and didanosine has been shown to enhance 
buccal permeation of didanosine (Ojewole 2009).  
 
3.1.7. Echinacea 
Echinacea was named after the Greek word “echinos”, meaning hedgehog, because 
of its large conical seed head which resembles the spines of an angry hedgehog 
(Grauds 2005). It is a North American plant genus found in the Atlantic drainage area 
east of the United States (US) and Canada. It is commonly known as coneflower, 
purple coneflower and American coneflower. (Briggs 2008) 
 
Echinacea has been used traditionally by North American Plain Indians extensively 
for medicinal purposes. It was famous in modern American medicine in the early 20th 
Century, and was discovered by Europeans, who are believed to have used it widely 
since the 1930s. Today millions of Europeans use Echinacea as their primary 
therapy for the common cold, flu and for general immune-boosting effects. (Leigh 
2001) Echinacea is believed to stimulate the immune system and has been used in 
the US for the prevention and treatment of colds, flus and other respiratory tract 
infections (Briggs 2008). It is now available on the South African market and is 
prescribed, by herbalists, as an immune boosting agent to HIV positive patients. Of 
the nine Echinacea species, only three, Echinacea angustifolia, Echinacea allid, and 
Echinacea purpurea, are used for medicinal purposes.  
 
Echinacea has tall stems with single pink or purple flowers and a central cone that is 
usually purplish-brown in colour. The large cone is a seed head with sharp spines 
that resemble a stiff comb. (Grauds 2005) 
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Figure 3.7: Echinacea pupurae (Source: Leigh 2008) 
 
Studies have shown that cichoric acid, a component of Echinacea is responsible for 
its HIV inhibitory effect by inhibiting the HIV integrase enzyme. Other polyphenolic 
compounds have also been shown to have antiviral activity. Anti-inflammatory 
activity differs between species and this activity is explained, at least in part, by the 
alkamide constituents which affect prostaglandin E2 production. Ethanol extracts 
from Echinacea roots have potent activity as agonists at TRPV1 receptors, which are 
mammalian pain receptors reported as integrators of inflammatory pain and 
hyperalgesia, and a prime therapeutic target for analgesic and anti-inflammatory 
drugs. The anti-inflammatory compounds identified to inhibit prostaglandin E2 
production differ from those involved in TRPV1 receptor activation. (Birt et al. 2008) 
With early intervention, a study carried out in 2003 suggests a positive effect of 
Echinacea in reducing symptom severity in subjects with upper respiratory tract 
infections, its immune stimulating effect is however still controversial (Goel 2003). 
 
In vitro investigations have shown Echinacea to be an inhibitor of CYP450 enzymes. 
It inhibits the activity of CYP1A2 enzymes and therefore affects the plasma levels of 
drugs metabolized by these enzymes. Echinacea has also shown to selectively 
modulate the catalytic activity of CYP3A at hepatic and intestinal sites. The type of 
interaction observed between Echinacea and other CYP3A substrates is dependent 
on the relative extraction of drugs at hepatic and intestinal sites. Caution should 
therefore be used when Echinacea is co-administered with drugs dependent on 
CYP3A or CYP1A2 for their elimination. (Gorski 2004) Concomitant use with 
protease inhibitors may result in increased blood drug levels (Aucamp 2008). 
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3.1.8. Carotenoids 
Carotenoids are a family of over 600 pigments from plants, 50 of which possess an 
unsubstituted ionone ring with vitamin A activity. Carotenoids have a strong 
antioxidant capacity, mostly through direct quenching or modification of free radicals 
in oxidative reactions. Some of the most prevalent carotenoids found in food sources 
include α-carotene, β-carotene, β-cryptoxanthin, lycopene, lutein, and zeaxanthin. 
Αlpha-carotene, β-carotene and β-cryptoxanthin are abundantly found in carrots and 
green leafy vegetables. Tomatoes are rich in lycopene whereas lutein is found in 
parsley and broccoli. (Webb 2007) 
 
Carotenoids effectively quench free radicals, a function that potentially protects 
immune cells from the damaging effects of reactive oxygen species (ROS) 
generated by the cellular respiratory burst (Webb 2007). Studies suggest that 
supplementation with carotenoids may enhance the functional capacity of Natural 
Killer (NK) cells and preserve phagocytic cells from reactive oxygen by either 
suppression of respiratory burst, or by quenching of the radical oxygen species 
(Salerno 2005). Evidence regarding the distribution and functions of leukocyte and 
lymphocyte subsets in HIV infected patients, on supplementation with carotenoids, is 
not conclusive (Webb 2007).  
 
Findings from several prospective studies indicate low plasma concentrations of 
carotenoids may predict progression of HIV infection and contribute to increased 
mortality. High intake of carotenoids by HIV positive patients, either from diet or 
supplementation, has been shown to reduce morbidity or enhance survival, possibly 
via the maintenance of CD4 counts. (Melikian et al. 2001)  
 
3.1.9. Honey 
Honey collection dates back at least 10 000 years, evidence of which can be found 
in Mesolithic paintings in Valencia, Spain. The paintings show two female honey-
hunters collecting honey and honey comb from a wild bee nest. (Crane 1986) 
Medicinal properties of honey have been cited in the Torah, the Bible and the Quran 
(Namias 2003). Referring to honey bees, the Quran states, “There comes forth from 
their bellies a beverage of many colours, in which there is healing for mankind” 
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(Surah Al-Nahal, verse 69). In the Bible, Solomon in Proverbs (24:13) advises, “My 
son, eat thou honey for it is good”. In Hinduism, honey is believed to be one of the 
five elixirs of immortality (Bhalla 2005). 
 
Honey is a natural product of bees of the genera Apis and Meliponinae. These bees 
collect nectar from flowering vegetation, and enzymatically process it, in vivo. The 
bees then deposit the processed nectar inside wax cells of their hives. Due to 
constant fanning by the bees, and the warmth created within the hive, the water 
content of the processed nectar is reduced by evaporation to 17%. The sugars in the 
nectar are converted to glucose and fructose. Glucose is then converted to 
glucuronic acid and hydrogen peroxide. The medicinal properties of honey are 
attributed to the pH, hydrogen peroxide, osmotic effect, and other unidentified 
compounds known as inhibines. (Namias 2003) 
 
Honey as an anti-infective agent has been used for wounds, including traumatic or 
surgical wounds, pressure ulcers and burns (Niamis 2003). Vardi and colleagues 
(1998) used honey as salvage therapy in one patient and recognised its efficacy 
against Pseudomonas aeruginosa and Staphylococcus aureus. They then created a 
standard protocol wherein, if a patient failed conventional intravenous treatment for a 
period of 14 days, honey would be initiated. Nine of their patients were reported to 
have benefited from the protocol. Investigations have also shown significant 
inhibitory effects of honey on Helicobacter pylori (Al Somal et al. 1994).  
 
In vitro studies reported inhibitory effects against HIV-1, the mechanism of which 
was, in part, via inhibition of viral entry. It was also found to have synergistic activity 
with zidovudine and no noticeable effect with indinavir. (Gekker et al. 2005) Natural 
honey also decreases prostaglandin levels, elevates nitric oxide production, and 
improves haematological and biochemical states in patients with a long history of 
AIDS (Noori et al. 2006).   
  
3.1.10. Nigella sativa 
Nigella sativa is commonly referred to as “black seed”, “kalonji”, “black cumin”, “love 
in the mist”, “Habba sawdaa” and “Shuneiz” (Tierra 2008 and Al-Jauziyah 1999). It is 
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grown mainly in the Middle East, Egypt, India, Pakistan and Afghanistan, and 
exported worldwide due to its extensive medicinal properties (Chishti 1991). The 
medicinal properties of this herb can be traced back thousands of years. Ancient 
Egyptians described it as a “panacea”, a cure for problems and diseases (Al-
Jauziyah 1999). Avicenna, in his ‘Canon of medicine’ states, “The black seed acts as 
an expectorant, stimulates the body’s energy and helps recovery from fatigue and 
dispiritedness” (Chishti 1991). Prophet Muhammad is reported to have said over 
1400 years ago, “use the black seed as it contains a healing for every kind of illness, 
except death” (Al-Jauziyah 1999).  
 
Nigella sativa belongs to the Ranunculacea family of herbaceous plants. It grows to 
a maximum height of 60cm, has blue flowers and finely divided foliage. Small 
caraway-type seeds are produced within the flowers. (Khan 1999) 
 
Figure 3.8: Nigella sativa (Katzer 2009) 
 
Nigella sativa has numerous active ingredients including thymoquinone, nigellone, 
nigellicine, arvacrol, nigellimine-N-oxide, nigellidine, thymohydroquinone, 
dithymoquinone, thymol, alpha-hedrin, oxy-coumarin, 6-methoxycoumarin and steryl-
glucoside. The herb also has a rich amount of tannins, flavonoids, essential amino 
acids and fatty acids, ascorbic acid, calcium and iron (Randhawa 2008). 
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Various therapeutic effects have been attributed to the Nigella sativa including 
antioxidant, anti-inflammatory, anticancer (Khalife 2007), antihistaminic (Kanter et al. 
2006), antibacterial (Morsi 2000), anti-asthmatic, analgesic, antifungal, 
hypoglycaemic, anti-parasitic, immuno-stimulatory, antiviral (Randhawa 2008) and a 
protective effect against ischemic reperfusion injury to various organs (Bayrak et al. 
2008). The herb also exerts an effect against HIV by inhibiting the HIV protease 
enzyme (Ma et al. 1994), and has an immuno-modulatory effect by increasing the 
number and activity of immune cells (Medenica et al. 1993 and Kandil et al. 1994). 
The seed powder, its oil and oral thymoquinone have been shown to be safe in 
animal studies (Zaoui et al. 2002, Badary et al. 1998 and Mansour et al. 2001). 
 
3.1.11. Zingiber officinale (Ginger) 
Zingiber officinale, more commonly known as ginger, is widely used for culinary 
purposes due to its characteristic aromatic odour. It is widely grown in Asia and has 
been used since ancient times for a variety of conditions including fevers, colds, 
digestive problems, and as an appetite stimulant. The strong aroma of ginger is 
mainly the result of gingerol, the extract primarily used in research studies. (White 
2007) 
 
Zingiber officinale is a perennial herb belonging to the Zingiberaceae family. The 
rhizome is horizontal, fleshy, branched, aromatic and yellowish to brown in color. Its 
stem is thick, leafy, and grows to a height of about 60cm. The leaves of this herb are 
pointed, narrow, approximately 20 cm long and 1.5 to 2cm wide. (Ross 2005) 
 
Ginger has been shown to be effective in motion sickness, nausea and vomiting, and 
vascular conditions. In pregnancy-induced nausea and vomiting, ginger was found to 
be comparable in efficacy to vitamin B6 and it was superior to placebo in post-
operative nausea and vomiting. A significant increase in fibrinolytic activity has also 
been found with 5 grams of ginger powder. In in vitro and animal studies, ginger has 
shown efficacy as an antioxidant, antimicrobial, antifungal, antineoplastic, and an 
antihypertensive agent. (White 2007)  
 
Adverse effects associated with ginger are uncommon, though mild gastrointestinal 
effects such as heart burn, diarrhoea and irritation in the mouth have been reported. 
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In animal models, ginger has been reported to cause a positive inotropic effect as 
well as arrhythmias. (White 2007)  
 
3.1.12. Oxygen therapy 
The immune system uses self-generated oxygen free radicals to destroy bacterial 
and viral infections. In much the same way oxygen therapy makes use of hydrogen 
peroxide, ozone, or hyperbaric oxygen in order to combat HIV. The additional 
oxygen atoms in hydrogen peroxide (H2O2) and ozone (O3) dissociate from the 
parent molecule and link to the invading molecules, altering their molecular structure. 
The harmful molecules are thereby killed, leaving behind only water (H2O) or oxygen 
(O2). (Trivieri and Anderson 2002) 
 
Studies cited by Wichtl (2004) show that when a group of patients, infected with HIV, 
herpes, and hepatitis, underwent ozone therapy, the number of T4 and T8 cells 
normalised in all cases, with no adverse effects. Ozone was also effective in 
reducing AIDS-related diarrhoea, and when treated in vitro with ozone, HIV was 
completely inactivated. In Baltimore, USA, Michelle Reillo of the Life Force 
Hyperbaric Oxygen Institute has been treating AIDS patients with hyperbaric oxygen. 
Reillo says, “Hyperbaric oxygen therapy is an ideal intervention in the individual 
recently infected with HIV, because it decreases viremia, is not toxic to the individual, 
and decreases the microvascular and neurovascular damage occurring as the initial 
infection progresses throughout the body” (Trivieri and Anderson 2002).  
 
NuScience Corporation from California, USA, is the manufacturer of Cell Food®, a 
product widely available on the South African market. They claim to be utilizing “a 
proprietary water-splitting technology that provides a powerful stream of bio-available 
oxygen plus 129 nutrients directly to the cells”. A preliminary study by Lunat (2008) 
found the use of Cell Food® was common amongst HIV-positive patients in the 
Eastern Cape. 
     
3.1.13. Magnesium and carnitine 
Magnesium is an essential mineral. Essential nutrients are those derived from foods 
that the body is unable to manufacture on its own and are highly necessary for the 
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normal functioning of the human body.  Magnesium is found in most nuts, fish, green 
vegetables, whole grain and brown rice. It helps against colds and flu, protects 
against the development of cancer, is necessary for the maintenance of pH in blood, 
and is also required for RNA and DNA synthesis. (Trivieri and Anderson 2002) 
 
Carnitine is amongst the non-essential nutrients called accessory nutrients or 
cofactors. These nutrients work with essential nutrients to aid in the breakdown and 
conversion of food into cellular energy. They help support the body’s physical and 
mental functions. They are considered non-essential as they can be synthesized by 
the body from essential amino acids. Carnitine is mainly found in meat and dairy 
products. It helps boost metabolism by helping the body burn fats more efficiently. It 
is considered the fork-lift that takes fat to the fat incinerators (mitochondria) in our 
cells. The entry of fat into the mitochondria is necessary for its metabolism. (Trivieri 
and Anderson 2002)  
 
Magnesium and L-carnitine levels are usually lower than normal in HIV-positive 
patients. Fatigue, lethargy and mental impairment in HIV are attributed, amongst 
other minerals and vitamins, to low magnesium levels. (Skurnick et al. 1996) 
 
Magogotha Carniboost®, also known as Carnimag®, is a patented combination 
product developed by Gotha Pharmaceuticals, South Africa. It was developed for 
carnitine and magnesium supplementation in deficiency states such as anorexia, 
kwashiorkor, diabetes and HIV. The product contains 100mg L-carnitine base, 
100mg magnesium chloride, 185mg magnesium oxide and 48mg crystallized water. 
Gotha Pharmaceuticals claims to have conducted studies in George, South Africa, 
reporting the doses in Carnimag® to be beneficial as supplementation, in deficiency 
states such as HIV (Van der Walt et al. 2009). The manufacturer also claims to be 
investigating the efficacy and safety of Carnimag® in preventing hyperlactinemia and 
lactic acidosis in patients on highly active ARV treatment. 
 
3.1.14. Other herbal preparations available on the South African market 
Apart from those mentioned above, there are still a wide variety of commercialised 
traditional herbal preparations on the South African market, readily available from 
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shops, herbal shops and pharmacies. Some of those recommended for HIV or 
symptoms of HIV by manufacturers include, by trade names: Amandla esambane 
No. 1®, Ibhubezi®, Ingungumbane Mahlabizifo®, Ingwe muthi mixtue®, Lion 
izifozonke®, Ngoma® herbal tonic, S’mangaliso® herbal mixture, Stametta 
BODicare®, Umpatisa inkosi® and Umuthi wekukhwehlela ne zilonda®. The majority 
of these do not specify their active ingredients. (Ndhlala 2009) Also available, 
amongst many others, are Swiss Garde products, Herbal Life products and Golden 
Neo-Life Diamite products.  
 
3.2. TCAM vs. CONVENTIONAL 
Conventional medicines are required to meet up to three vital concepts: quality, 
safety and efficacy. Although they have a discouraging side-effect profile, these 
medicines have undergone rigorous clinical trials to prove their safety and efficacy in 
HIV-positive patients. With industry Good Manufacturing Practice (GMP), patients 
are, in most cases, assured of a good quality product. On the other hand, the 
majority of the herbal remedies mentioned in section 3.1 may show some promise in 
the fight against HIV, however, the evidence available for most is only anecdotal 
and/or in vitro in nature, and many of the private herbal entrepreneurs seem not to 
conform to GMP (Mander et al. 2007). Quality control regarding traditional medicines 
may be worrying as they are sold on pavements and in markets where possibilities of 
contamination are numerous. With regards to safety and efficacy, besides the 
contamination, clinical evaluation of traditional medicines may be difficult as healers 
and herbalists are not ready to give up their traditional ‘secret remedies’. (Ndhlala 
2009) 
 
Without substantial evidence, some researchers, such as Malan (2008), believe that 
the use of herbal remedies, especially those with immune boosting potential, should 
not be recommended in HIV-positive patients. Malan believes stimulation of the 
immune system could be more harmful than beneficial. This is because the immune 
system exists in two states, active and inactive, and it is difficult if not impossible, for 
the HIV virus to infect an inactive immune cell. Infected cells also need to be 
activated to produce HIV particles. The consequence is that anything that stimulates 
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the immune system has the potential to increase the production of the virus by 
infected cells, as well as to increase the vulnerability of uninfected cells to HIV. He 
also believes that apoptosis, or programmed cell death in the immune system, will be 
stimulated by immune boosters. 
 
Various herbal products, including herbal teas, were recently withdrawn from the US 
market. A herbal tea marketed for weight loss was withdrawn from the US and 
European markets on safety grounds, reporting that it could potentially cause heart 
attack and stroke (Woodfield 2010). Such studies show the necessities of carrying 
out clinical trials on remedies available for use in the general population. A study 
carried out in North America reported natural supplements which cost as little as $3-
$4 (ZAR21-28) per month were actually those which had good supporting evidence 
of efficacy, whilst those for over $20 (ZAR140) per month were simply heavily 
promoted, with no supporting evidence (Temple 2010). In Europe, as of the year 
2011, the European Union will require all those practitioners providing herbal 
medicines to show they have the right training and experience, abide by a code of 
conduct and ensure they have insurance in place. Only statutorily registered 
professionals will be allowed to prescribe herbal remedies. (Dunn 2010) 
 
The variety of ARV drugs, especially in Africa, is limited. Additionally, due to non-
adherence to medication because of discouraging side-effects, as well as the advent 
of ‘whoonga’, resistance issues are highly concerning. ‘Whoonga’ is a drug 
commonly smoked in the local townships of Durban, and growing in popularity in 
other parts of the country. It is a blend of detergent powder, rat poison and crucially 
crushed ARVs, added to marijuana. The drug is sold by dealers for R20 a hit, with 
multiple hits needed by smokers to get through the day. Many in the poor 
communities survive on as little as R15 per day, therefore crime has become the 
only way to secure a regular supply of ‘whoonga’. Many HIV-positive patients in need 
of ARVs have to go without their medication as they are constantly being mugged by 
drug addicts. Others, having a constant supply of ‘free ARVs’ from the government, 
sell them, as the value of the drugs may seem more pressing to the poor than their 
life saving drugs. Also of concern, is that clinic staff members are increasingly 
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enticed into selling ARVs directly to addicts or dealers. Some individuals reportedly 
seek to become HIV-positive themselves, just to get their supplies for free. Although 
the police and the national addiction council say they are doing everything they can, 
the fight against this drug seems uncontrollable. (Hull 2010)  
 
Bearing TCAMs in mind, as potential alternatives, the possible repercussions that 
could arise from ‘whoonga’ should be one reason to step up close partnerships with 
TCAM practitioners, as resistance issues will not only cause serious public health 
concerns, but also, with a limited number of ARV alternatives, patient confidence in 
the HCPs may further decline.   
 
3.3. PURPOSE OF STUDY 
This exploratory study investigated the extent to which TCAMs are being 
recommended and the extent to which they are being used by HIV-positive patients 
prior to and during ARV therapy. Such a study could help HCPs understand the 
extent of TCAM use by HIV-positive patients in South Africa and may have important 
clinical implications for patients prior to and on antiretroviral medication.  
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Chapter 4 
METHODOLOGY 
4.1. INTRODUCTION 
A preliminary study was conducted in 2008 to determine the extent to which herbal 
immune boosters/modulators were being prescribed to HIV-positive patients in the 
Eastern Cape, prior to the initiation of ARV therapy. The investigation was carried 
out using telephonic surveys with various Health Care Professionals (HCPs) and 
non-HCPs involved in the management of HIV in the Eastern Cape. Of the 17 HCPs 
interviewed, 23.53% (4; n=17) recommended the use of herbal immune boosters, but 
only 5.88% (1; n=17) were actually prescribing them. The immune boosters being 
prescribed were Sutherlandia frutescens and Lobostemon fruticosus. (Lunat 2008) 
Based on the experience from this preliminary study, the current study investigated 
the extent to which traditional, complementary and alternative medicines were being 
prescribed by TCAM practitioners/providers and HCPs, and used by HIV-positive 
patients, prior to and during ARV therapy in the Nelson Mandela Bay Municipality. 
 
4.2. LITERATURE REVIEW 
An in depth literature review of HIV/AIDS in general and the use of TCAMs in the 
self-treatment and management of HIV-positive patients, prior to and during ARV 
therapy was undertaken.  
 
4.3. RESEARCH DESIGN 
The study was an exploratory, cross sectional, observational study. Data was 
collected from the participants on one occasion only, making it cross-sectional in 
nature (Smith 2005). Cross sectional studies, also known as surveys, allow the 
gathering of information on important health-related issues such as peoples’ 
knowledge, attitudes and practices (Last 2002). No interventions were made during 
the study, and it was exploratory in nature, investigating the use of TCAMs in the 
treatment of HIV/AIDS, from the perspective of different stakeholders, including 
HCPs, TCAM practitioners/providers and HIV-positive patients (Smith 2005).  
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4.4. RESEARCH SAMPLE 
Although the initial target was the whole of the Eastern Cape, due to time and 
budgeting constraints, the research sample was selected from the Nelson Mandela 
Bay Municipality only. The population of the Eastern Cape is approximately 7.1 
million, of which 1.5 million people reside in the Nelson Mandela Bay Municipality 
(Eastern Cape Development Corporation 2008). According to a study carried out by 
the Department of Health (2005), 8.9% of the population in the Eastern Cape were 
estimated to be HIV-positive.  
 
There are eight hospitals and 57 clinics or community health centres within the 
Nelson Mandela Bay (Department of Health 2008). There are also a number of 
private health care facilities in the Eastern Cape. 
  
Participants for the study were selected via convenience sampling and included 
three distinct populations (Figure 4.2), as follows: 
 
a) HCPs 
HCPs included doctors and registered nurses who were involved in the 
prescribing and dispensing of medication in the Nelson Mandela Bay 
Municipality (Figure 4.2). A contact list of the HCPs at government health 
facilities was requested from the Department of Health and the Nelson 
Mandela Bay Municipality. Contact details of private health facilities in the 
Municipality were obtained from individuals affiliated to the HIV Clinicians 
Society. This was in order to target practitioners in both the public and private 
sectors.  Practitioners were invited to participate in the study by the 
researcher. Only those indicating a willingness to participate3, and who were 
able to speak English, were included in this arm of the study. A targeted 
minimum of 25 HCPs, from each sector, were to be recruited for participation.  
 
 
 
                                                
3
 Verbal consent was obtained from those participants participating in the study via telephonic interviews. 
Participants interviewed personally were required to complete a written consent for their willingness to 
participate 
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b) HIV-positive patients  
HIV-positive patients were selected from primary health care facilities within 
the Nelson Mandela Bay Municipality (Figure 4.1 and 4.2). Invitations for 
participation were sent to: 
 
• Private health care facilities 
• Public health care facilities, including: 
o Port Elizabeth Hospital Complex; targeting major hospitals in 
the Nelson Mandela Bay 
o Nelson Mandela Bay Municipality; targeting ARV and non-
ARV clinics in all three sub-districts of the Nelson Mandela 
Bay (Refer Figure 4.1) 
 
Of those invited, the Nelson Mandela Bay Municipality and two private health 
care facilities gave permission to conduct the study at their sites. The 
Municipality gave permission to carry out the study at three ARV clinics and 
three non-ARV clinics servicing HIV positive patients, each from sub-districts 
A, B and C.  
 
After obtaining written authorisation to conduct the study, HIV-positive 
patients (over the age of 18) were recruited from the private health care 
facilities and the Municipal clinics. These patients were invited to participate in 
the study by the attending staff at the facilities4. Only patients who indicated 
willingness to participate were introduced to the researcher. The researcher 
then explained the purpose of the study to the patients. Only those patients 
who provided the researcher with a signed written consent were included.  
 
  
                                                
4
 In the case of patients who did not speak English, the attending staff notified the patients of the presence of a 
third party, the translator, who was from the health care profession and was required to sign a declaration of 
confidentiality. 
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Participants 
 
Sector 
 
 
Clinic 
 
Region 
 
 
 
 
c) Traditional, complementary and alternative medicine practitioners/providers 
(TCAMPs)  
TCAMPs were recruited within the Nelson Mandela Municipality area (Figure 
4.2) and included a wide range of practitioners/providers, namely: 
 
 Herbalists  
 Homeopaths  
 Naturopaths 
 Traditional healers 
 Religious practitioners 
 Nutritional counsellors 
 Shops keepers 
 
Traditional healers, traditional herbalists and shops were easily located since 
they operate from the roadside of many streets of the city centre. The contact 
details of some TCAMPs and health shops were acquired from the yellow 
pages of the Eastern Cape telephone directory. Others were introduced to the 
researcher by the HIV positive participants. The TCAMPs were invited to 
participate in the study by the researcher. Only those TCAMPs who were able 
HIV-
positive  
patients 
Public 
sector 
Sub- 
district 
A 
Private 
sector 
Sub- 
district  
B 
Sub- 
district 
C 
Sub- 
district 
C 
Sub- 
district 
A 
Sub- 
district 
B 
Sub- 
district 
B 
Non-ARV 
clinic  
ARV clinic 
Sub- 
district 
A 
ARV clinic 
Figure 4.1: Overview of the participating health care facilities 
65 
 
 
to speak English and indicated a willingness to participate in the study5 were 
recruited. A minimum of 30 TCAMPs were targeted for participation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                                                
5
 Verbal consent was obtained from those participants participating in the study via telephonic interviews. 
Participants interviewed personally were required to complete a written consent for their willingness to 
participate 
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Figure 4.2: Overview of the research population and setting 
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4.5. DATA COLLECTION 
Data collection took place over a six month period, from June 2009 to November 
2009, using purpose-designed data collection forms. Provisional data collection 
forms were developed and piloted with a minimum of four participants in each of the 
respective target groups. The results of the pilot studies were not included in the final 
results. The pilot studies were conducted to ascertain the acceptability and feasibility 
of the method and procedure in a research setting. These pilot interviews were also 
used to ensure that the chosen research method collected the data required, in 
terms of completeness, reliability and validity, in order to meet the study objectives 
(Smith 2005). After each pilot interview, the data collection forms were modified 
accordingly (Figure 4.3). The following data collection tools were developed: 
  
a) HCPs: Researcher-administered HCP interview questionnaire (Appendix 1(a)) 
The pilot interviews with the provisional tool were carried out, and no 
modifications were necessary. The final tool was then used to collect data 
using semi-structured telephonic and personal interviews with HCPs involved 
in HIV management in the Nelson Mandela Bay Municipality (Figure 4.3).  
 
b) TCAMPs: Researcher-administered TCAMP interview questionnaire 
(Appendix 1(b)) 
Following the pilot interview, this provisional tool also did not require any 
modifications. It was used to collect data using semi-structured personal 
interviews with TCAMPs within the Nelson Mandela Bay Municipality (Figure 
4.3). 
 
An appointment for the interview was made with the HCPs and TCAMPs. 
Following verbal consent for participation, the participants were mailed, faxed, 
e-mailed or provided with a copy of the questionnaire prior to the interview.6 A 
preview of the questionnaire prior to the interview allowed participants time to 
look up relevant information that may not have been readily available. Data 
was then collected, using the semi-structured interview forms, at the time of 
                                                
6
 The Preliminary study carried out by Lunat (2008) showed a possible inaccuracy of results when 
participants were interviewed without prior knowledge of the questions in the questionnaire. 
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the interview. Some TCAMPs and HCPs preferred to fill out the 
questionnaires themselves, and later allowed time for questions from the 
researcher. Those who were interviewed by the researcher were required to 
give written consent prior to participation.   
 
c) HIV-positive patients: Researcher-administered patient questionnaire 
(Appendix 1(c)) 
Following verbal consent for participation, obtained by the HCP at the clinics, 
patients were introduced to the researcher. The study was explained to the 
participants who were also provided with a written copy of a structured 
preamble to the study (Appendix 2), and a written consent for their 
participation was obtained. Researcher-administered patient interviews were 
then conducted in-person, during which the finalised questionnaire7 was used 
to collect data (Figure 4.2 and 4.3).  
 
 
 
                                                
7
 After piloting at a private health care facility, with four patients providing signed written consent for 
the interview, modifications were made. An additional question was added to the questionnaire, 
asking if patients were aware of others using TCAMs. 
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Figure 4.3: An overview of the research methodology 
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4.6. DATA ANALYSIS 
Microsoft Excel® was used for the capture of data from the questionnaires. In order 
to ensure consistency and accuracy, the researcher personally entered all the data. 
Statistica® software, version 9.0, was used for the purpose of statistical analysis. 
Guidance and assistance with the analysis was provided by a statistician.  
 
The frequency and type of TCAM therapy was presented as percentages and cross-
tabulation was used to determine the prevalent reasons for TCAM use. The Pearson 
Chi-squared test was used to investigate statistical differences in TCAM use 
amongst ARV and non-ARV populations.  
 
4.7. ETHICAL CONSIDERATIONS 
Ethical approval to conduct the study was obtained from the Faculty of Health 
Sciences Research Technology and Innovation Committee and the NMMU Research 
Ethics Committee (Human). (Ref: N 01/11/03/07 [H09-HEA-PHA-003/Approval]) 
 
Permission to carry out the study was obtained from the director of PHC Services for 
the Nelson Mandela Bay Municipality Clinics, as well as from the directors of the two 
private health care facilities (Appendix 3).  
 
Informed consent was obtained from all participants included in the study and the 
following points need to be noted: 
 
• An introductory preamble to the questionnaire was read to the HCPs 
participating via telephonic interviews, and their verbal consent to participate 
in the study was obtained 
• A written introductory preamble was given to participants being interviewed 
face-to-face, and their written consent for participation was obtained 
• A translator was only used for patients who did not speak English, and was 
required to sign a declaration of confidentiality in the presence of each of the 
participants 
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No participant-identifying details were recorded on the data collection forms and all 
information received was treated with utmost confidentiality.  
 
The signed written consent forms and questionnaires were kept in two separate files 
to prevent linking patient response to their identity.  
 
The statistician consulted, had access only to the data collection tools, and had no 
access to participant-identity.  
 
All information collected from the participants during the study was kept safely locked 
up in the pharmacy department at NMMU, and is accessible only to the researcher.  
 
In the reporting of data, no identifying details of any individual participant or facility 
were divulged.  
 
The study was conducted in accordance with the ethical principles of the Declaration 
of Helsinki (World Medical Association 2002). 
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Chapter 5 
RESULTS AND DISCUSSION 
 
5.1. INTRODUCTION 
This chapter will report on and discuss, in depth, the use of TCAMs by the sample 
population of HIV positive participants. It also provides an analysis of the patient 
context, including patient socio-demographics, health characteristics and clinical 
management. The extent and types of TCAMs prescribed for the management of 
HIV, by HCPs, and TCAM practitioners will also be discussed. 
  
5.2. ANALYSIS OF THE TOTAL STUDY POPULATION 
For the purpose of this study, data was collected over a period of six months from 
three distinct populations, namely: 
• HIV positive patients; 
• HCPs; and 
• TCAM practitioners. 
 
5.2.1. HIV positive patient population 
Participants for this sample were selected from clinics in Sub-districts A, B and C of 
the Nelson Mandela Bay Municipality.  
 
A total of seven clinics took part in the study, of which two are private sites and five 
Municipal sites. Three of these Municipal sites and both private sites are ARV clinics. 
The remaining two Municipal clinics are not ARV sites although they are involved in 
the management of HIV positive patients prior to the initiation of ARVs.   
 
The HCPs (n=29) interviewed at these clinics reported an approximate monthly total 
of 148 149 patients, of which 31 940 (21.56%) were HIV positive. Amongst the HIV 
positive patients, 12 792 (40.05%) were not eligible for ARV treatment. 
 
A total of 244 HIV positive patients were interviewed by the researcher, of whom 138 
(56.56%) patients were undergoing ARV treatment and 106 (43.44%) were not on 
 ARVs (Figure 5.1). Those not on ARVs 
ARVs, as well as those who had defaulted and therefore discontinued. 
patients not eligible for ARV treatment
reason being a high CD4 count; 19 (65.52%; n=29) due
and 24 (82.76%; n=29) due to a lack of 
Figure 5.1: HIV positive patients interviewed (n = 244)
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(65.98%) participants were single and had never been married prior to the interview, 
whilst 46 (18.85%) were married at the time
 
The majority of the population had some educational background, with 
patients having reached secondary school
the general educational level of the patients visiting the
sample may be due to the fact that only those fluent in the English language were 
included in the study.  
  
Non
patients
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73 
included both, patients not yet initiated on 
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adherence. 
 
was female, with only 69 (28.28%) of the 
pants varied from 18 to over 65 years, with 
n the 26 to 45 age group. Only two ethnic groups 
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Considering living conditions, 187 (76.64%) participants were from established 
townships, whilst 41 (16.80%) lived in informal settlements. With regards to 
employment, 162 (66.39%) participants were unemployed. Of those unemployed, 
123 (50.41%) participants relied on family members for support; 44 (18.03%) on 
government grants; and 13 (5.33%) participants had no source of income. Table 5.1 
below shows the overall socio-demographics of the sample population: 
 
Table 5.1: Socio-demographics of the sample population 
 
Patient 
Total 
patients 
(n = 244) 
ARV 
patients 
(n = 138) 
Non-ARV 
patients 
(n = 106) 
Gender    
Male 
Female 
69 (28.28%) 
175 (71.72%) 
36 (26.09%) 
102 (73.91%) 
33 (31.13%) 
73 (68.87%) 
Age    
18-25 
26-35 
36-45 
46-55 
56-65 
65+ 
31 (12.70%) 
87 (35.66%) 
87 (35.66%) 
30 (12.29%) 
5 (2.05%) 
4 (1.64%) 
11 (7.97%) 
50 (36.23%) 
55 (39.85%) 
19 (13.77%) 
2 (1.45%) 
1 (0.72%) 
20 (18.87%) 
37 (34.91%) 
32 (30.19%) 
11 (10.38%) 
3 (2.83%) 
3 (2.83%) 
Home language    
Xhosa 
Afrikaans 
English 
Swahili 
197 (80.74%) 
45 (18.44%) 
1 (0.41%) 
1 (0.41%) 
113 (81.88%) 
23 (16.67%) 
1 (0.72%) 
1 (0.72%) 
84 (79.24%) 
22 (20.75%) 
0 (0.00%) 
0 (0.00%) 
Ethnicity    
Black 
Coloured 
200 (81.97%) 
44 (18.03%) 
115 (83.33%) 
23 (16.67%) 
85 (80.19%) 
21 (19.81%) 
Religious affiliation    
Christian 
Traditional 
Christian/traditional 
None 
122 (50.00%) 
18 (7.38%) 
102 (41.80%) 
2 (0.82%) 
76 (55.07%) 
8 (5.80%) 
53 (38.41%) 
1 (0.72%) 
46 (43.40%) 
10 (9.43%) 
49 (46.23%) 
1 (0.94%) 
Marital status    
Single 
Married 
Cohabiting 
Divorced 
Widowed 
161 (65.98%) 
46 (18.85%) 
1 (0.41%) 
21 (8.61%) 
15 (6.15%) 
92 (66.67%) 
24 (17.39%) 
0 (0.00%) 
15 (10.87%) 
7 (5.07%) 
69 (65.09%) 
22 (20.75%) 
1 (0.94%) 
6 (5.66%) 
8 (7.55%) 
Highest education    
None 
Primary 
Secondary 
Post-secondary 
Tertiary 
8 (3.28%) 
70 (28.69%) 
139 (56.97%) 
20 (8.20%) 
7 (2.87%) 
1 (0.72%) 
34 (24.64%) 
82 (59.42%) 
16 (11.59%) 
5 (3.62%) 
7 (6.60%) 
36 (33.96%) 
57 (53.77%) 
4 (3.77%) 
2 (1.89%) 
Residence    
Informal 
Suburban 
Township 
41 (16.80%) 
16 (6.56%) 
187 (76.64%) 
19 (13.77%) 
11 (7.97%) 
108 (78.26%) 
22 (20.75%) 
5 (4.72%) 
79 (74.53%) 
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Patient 
Total 
patients 
(n = 244) 
ARV 
patients 
(n = 138) 
Non-ARV 
patients 
(n = 106) 
Employment status 
Self employed 
Employed 
Casually employed 
Unemployed 
Retired 
Student 
Unable to work 
15 (6.15%) 
50 (20.49%) 
16 (6.56%) 
162 (66.39%) 
0 (0.00%) 
1 (0.41%) 
0 (0.00%) 
9 (6.52%) 
35 (25.36%) 
11 (7.97%) 
83 (60.14%) 
0 (0.00%) 
0 (0.00%) 
0 (0.00%) 
6 (5.66%) 
15 (14.15%) 
5 (4.72%) 
79 (74.53%) 
0 (0.00%) 
1 (0.94%) 
0 (0.00%) 
Source of income    
Business 
Salary/wages 
Family 
Government grant 
No income 
15 (6.15%) 
63 (25.82%) 
123 (50.41%) 
44 (18.03%) 
13 (5.33%) 
9 (6.52%) 
43 (31.16%) 
55 (39.85%) 
36 (26.09%) 
6 (4.35%) 
6 (5.66%) 
20 (18.87%) 
68 (64.15%) 
8 (7.55%) 
7 (6.60%) 
 
Of the study sample, 70 (28.69%) participants had been aware of their HIV status for 
one to three years at the time of the interview; 68 (27.87%) for over five years; and 
51 (20.90%) for three to five years. The CD4 counts of the patients varied widely, 
with 72 (29.51%) participants having a count of over 350 cells/mm3; 30 (12.29%) 
ranging between 300 to 349 cells/mm3; and 28 (11.47%) between 200 and 249 
cells/mm3. The majority of the patients, 170 (69.67%), when asked their personal 
perception about their health said they were feeling good. Table 5.2 below shows 
some of the health characteristics of the sample population.  
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Table 5.2: Health characteristics of the sample population 
 
Patient 
Total 
patients 
(n = 244) 
ARV 
patients 
(n = 138) 
Non-ARV 
patients 
(n = 106) 
Period of status awareness    
< 3 months 
3 – 11 months 
1– 3 years 
3 – 5 years 
> 5 years 
24 (9.84%) 
31 (12.70%) 
70 (28.69%) 
51 (20.90%) 
68 (27.87%) 
2 (1.45%) 
12 (8.70%) 
42 (30.43%) 
35 (25.36%) 
47 (34.06%) 
22 (20.75%) 
19 (17.92%) 
28 (26.41%) 
16 (15.09%) 
21 (19.81%) 
CD4 count (cells/mm
3
)    
0 – 49 
50 – 99 
100 – 149 
150 – 199 
200 – 249 
250 – 299 
300 – 349 
> 350 
Unknown 
7 (2.87%) 
17 (6.97%) 
23 (9.43%) 
21 (8.61%) 
28 (11.47%) 
24 (9.84%) 
30 (12.29%) 
72 (29.51%) 
22 (9.01%) 
3 (2.17%) 
12 (8.70%) 
12 (8.70%) 
15 (10.87%) 
19 (13.77%) 
13 (9.42%) 
19 (13.77%) 
42 (30.43%) 
3 (2.17%) 
4 (3.77%) 
5 (4.72%) 
11 (10.38%) 
6 (5.66%) 
9 (8.49%) 
11 (10.38%) 
11 (10.38%) 
30 (28.30%) 
19 (17.92%) 
Personal opinion of health    
Very poor 
Poor 
Fair 
Good 
Excellent 
1 (0.41%) 
15 (6.15%) 
53 (21.72%) 
170 (69.67%) 
5 (2.05%) 
0 (0.00%) 
5 (3.62%) 
27 (19.56%) 
102 (73.91%) 
4 (2.90%) 
1 (0.94%) 
10 (9.43%) 
26 (24.53%) 
68 (64.15%) 
1 (0.94%) 
    
 
5.2.2. HCP population 
A total of 29 HCPs from 11 clinics in the Nelson Mandela Bay Municipality took part 
in the study. Of this HCP population, six (20.69%) participants were interviewed 
telephonically, whilst 23 (79.31%) were interviewed in person. The HCPs included 
seven (24.14%) doctors and 22 (75.86%) nurses from both the public and private 
sectors (Figure 5.2).   
 Figure 5.2: HCPs involved in the management of HIV (n=29), interviewed 
clinics in the NMB Municipal
 
5.2.3. Traditional Complementary and Alternative Medicine Practitioners 
(TCAMPs) 
This population included 30 TCAMPs from with
Municipality. A variety of TCAMPs took part in the study including 
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homeopath; and eight (26.68%
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 Figure 5.3: TCAM practitioners (n=30) from NMB Municipality, interviewed 
regarding HIV management
 
5.3. ANALYSIS OF THE USE 
Amongst the total HIV positive sample population, 69 (28.28%; n=244) patients were 
using TCAMs (these exclude patients using ‘life
175 (71.72%; n=244) patients were not (Figure 5.4). 
Figure 5.4: Extent of TCAM use amongst the HIV positiv
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2008). A 
 
 study in Gauteng and Mpumalanga revealed 37 (84%; n=44) participan
traditional medicines for the management of HIV at some point in time, whilst 14 
(32%; n=44) were still using them at the time of the investigation (Babb 
An Australian study showed up to 49% of its participants were using TCAMs fo
management of HIV/AIDs (Thomas 
 
Of the patients using TCAMs in this investigation
on ARV treatment (Figure 5.5). The remaining 38 (35.85%; n=106) patients, although 
not on ARVs, may have been on other medications such as co
treatment, multivitamins, etc.  
Figure 5.5: Extent of TCAM use amongst th
 
The use of TCAMs by these patients may have direct implications on their 
therapeutic outcome due to possible drug/TCAM interactions (Harnett 2004), as well 
as on the progression of their condition due to possible effects on th
system (Malan 2008). 
 
5.3.1. Socio-demographics 
This section will attempt to find a relationship between patient socio
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 a) Gender 
Amongst the total HIV positive sample population (n=244), 28.00% of females 
(n=175) used TCAMs, compared with 28.99% (n=69) males. 
 
Of the 102 females on ARVs, 23.53% (24) used TCAMs, compared with 
19.44% of males (7; n=36). Similarly with those patients 
of females (25; n=73) and 39.39% of the males (13; n=33) used TCAMs. 
(Figure 5.6)  
 
 
Figure 5.6: Gender relationship to TCAM use amongst ARV and non
The Pearson χ2 test applied to the results indicated no statistical difference 
between gender and the use of TCAMs amongst ARV and non
(χ2 = 1.1218; df = 1; P > 0.05).
 
b) Age 
An analysis of the total sample population (n=244) revealed the use of TCAMs 
increases as age increases, with the elderly being most likely to use TCAMs 
compared with the younger generation (Figure 5.7). 
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A comparison of the ARV and non
difference between age groups and the use of TCAMs when the Pearson 
test was applied (χ2 = 2.77906; df = 3; P > 0.05). Of the 11 patients in the 18
25 age group who were on ARVs, 9
25.00% of those not on ARVs (5; n=20). A similar trend persisted as age 
increased, with non-ARV patients showing a greater likelihood of using 
TCAMs. In the 46-55 age group, the likelihood amongst the ARV and non
ARV patients was similar, with 36.84% (7; n=19) and 36.36% (4; n=11), 
respectively. The population size over the age of 56 was not large enough for 
conclusive results. (Figure 5.8)   
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 Figure 5.8: Age relationship to TCAM use amongst ARV and non
 
c) Ethnicity 
Only those of black and coloured ethnicity participated in the study. Within 
these populations, 45.45% (20; n=44) of coloureds used TCAMs, compared 
with 24.50% (49; n=200) blacks. 
 
A comparison of the ARV and non
n=21) of coloureds not on ARVs, whilst 39.13% (9; n=23) of those on ARVs, 
used TCAMs. Amongst those of black ethnicity, 31.76% (27; n=85) non
patients, whilst 19.13% (22; n=115) ARV patients used TCAMs. These results 
show coloureds, amongst both A
likely to use TCAMs compared with those of black ethnicity. (Figure 5.9) 
Statistically though, the Pearson 
between ethnicity and the use of TCAMs amongst ARV and non
(χ2 = 0.008947; df = 1; P > 0.05).
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 Figure 5.9: Age relationship to TCAM use amongst ARV and non
d) Religious affiliation 
A wide range of religious beliefs exist in South Africa. However, only those of 
Christian and traditional beliefs 
of the relative sizes within the entire population (n=244) indicated no 
significant relationship between religion and the likelihood of using TCAMs. 
Amongst the Christians, 24.59% (30; n=122) participants used
33.33% (6; n=18) held traditional beliefs. Of the participants who held both 
Christian and traditional beliefs, 32.35% (33; n=102) used TCAMs.
 
Participants who were not on ARVs used TCAMs more commonly amongst 
the Christian population and t
whilst more of those with only traditional beliefs used TCAMs whilst 
undergoing ARV treatment. Of the 76 Christians on ARVs, 18.42% (14) were 
using TCAMs, compared with 34.78% (16; n=46) of those not on ARV
Similarly, 26.42% (14; n=53) ARV patients, and 38.78% (19; n=49) non
patients, with both Christian and traditional beliefs, used TCAMs. Of the 
participants who held traditional beliefs alone, 37.50% (3; n=8) of the ARV 
patients and 30.00% (3; n=10) 
The Pearson χ2 indicated no statistical difference between religious affiliation 
and the use of TCAMs amongst ARV and non
= 2; P > 0.05). 
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e) Marital status 
Amongst the entire HIV positive sample population (n=244), patients who 
were cohabiting seemed most likely to use TCAMs, 100.00% (1). However, 
this result cannot be genera
category. Those cohabiting were followed by the widowed, 40.0% (6; n=15), 
and divorced 38.10% (8; n=21). The single and married groups used TCAMs 
the least, 26.09% (42; n=161) and 26.09% (12; n=46), respectiv
these results could not be generalised due to a large variation in the sample 
sizes, age analysis had revealed an increase in TCAM use as age increases. 
It could therefore be assumed that the widowed patients are more likely to use 
TCAMs as the majority of them were amongst the elderly.
 
ARV patients who are single, married, cohabiting and divorced seem less 
likely to use TCAMs compared with the non
patients on ARVs seemed more likely to use TCAMs compared with those not 
on ARVs (Figure 5.11). A comparison 
however revealed no statistical difference when the Pearson 
applied (χ2 = 0.186325; df = 3; P > 0.05).
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f) Level of education 
As mentioned earlier, due to a lack of translators in most settings, the majority 
of the participants in the study were those who were able to converse in 
English. As a result the majority of the participants were educated. An 
analysis relative to the total HIV positive sample population (n=244) 
interestingly revealed those with no education used TCAMs the most, 50.00% 
(4; n=8), followed by those with a tertiary education, 42.86% (3; n=7). 
Participants with a secondary level education had 32.37% (
users, whilst those with a post
Patients with primary education had the least, with 22.86% (16; n=70) of its 
population using TCAMs.
 
A comparison of the ARV and non
significant difference when the Pearson 
2; P < 0.05). These differences can be noted amongst the uneducated, those 
with a primary education, and those with a tertiary education. ARV patients 
amongst the uneducated and those with a tertiary education seemed much 
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 more likely to use TCAMs compared with non
patients were much more likely to use TCAMs amongst patients with a 
primary education. However, there was only one uneducated ARV p
therefore the result in this category cannot be generalised. (Figure 5.12)
Figure 5.12: Education relationship to TCAM use amongst ARV and non
 
g) Residence 
Participants in the study came from informal settlements, suburbs and 
established townships. Although a higher number of TCAM users were from 
townships, an analysis of the total sample population reveals a higher relative 
use of TCAMs in suburban areas, 43.75% (7; n=16). The use by patients from 
townships and informal settle
24.39% (10; n=41), respectively.
  
No statistical difference was revealed when the Pearson 
the results, with non-ARV patients from all types of residences using TCAMs 
more frequently than the A
5.13).  
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 Figure 5.13: Residence relationship to TCAM use amongst ARV and non
 
h) Employment 
Results showed those who were self
40.00% (6; n=15), followed by the 
Amongst the unemployed, 28.40% (46; n=162) used TCAMs, and those 
employed, 22.00% (11; n=50). Only one student took part in the study and 
was found not to be using TCAMs, 0.00% (0; n=1).
 
The Pearson χ2 test applied to 
between employment status and the use of TCAMs amongst ARV and non
ARV patients (χ2 = 8.08852; df
amongst the self-employed, employed, casually employed and the 
unemployed. The non
employed and unemployed were much more likely to use TCAMs in 
comparison with the ARV patients, whilst the ARV patients who were 
employed used TCAMs more commonly compared with the non
patients. Amongst the self employed, 33.33% (3; n=9) ARV patients, whilst 
50.00% (3; n=6) non-ARV patients, used TCAMs. Those casually employed 
had 27.27% (3; n=11) ARV patients using TCAMs, compared with 60.00% (3; 
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 n=5) non-ARV patients. The unemployed pati
ARV patients using TCAMs, with 37.97% (30; n=79) non
student sample sizes are necessary for conclusive results amongst that 
category. (Figure 5.14) 
 
Figure 5.14: Employment relationship to TCAM use amongst
 
Individual characteristics such as religion, ethnicity, culture and education influence 
the self care behaviour of an individual (Chang 
demographic data of the ARV and non
relationship between TCAM use and age, ethnicity, marital status, education, 
residence and employment. The likelihood of using TCAMs was found to be 
increasing with age, and most common amongst the coloureds (45.45%), the 
widowed (40.0%), the uneducated (50.00%) followed by the highly educated 
(42.86%), and those from the suburbs (43.75%) who were self
Chang and co-workers (2003) found the ethnicity of the majority of CAM users in 
their study in the United States was Hispanic 
Eisenberg and colleagues (1998) reported highest use in the white population, 77%. 
An investigation carried out by Dhalla and colleagues
showed an association of CAM use with levels of educa
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which is consistent with other studies by Ostrow et al. (1997), Blais et al. (1997) and 
Eisenberg et al. (1997). Many studies have also found an association between CAM 
use and higher incomes (Dhalla et al. 2006, Blais et al. 1997, Eisenberg et al. 1997 
and Duggan et al. 2001), though Furler and colleagues (2003) reported an 
association with unemployment in Canada. Dhalla and co-workers (2006) explain the 
unemployment link to the patients being disabled, and as a result receiving a 
disability grant enough to afford CAM therapies. HIV positive patients in South Africa 
receive a grant when their CD4 count is below 200 cells/mm3, though the grant may 
not be as much as those in Canada or that of the suburban self-employed in South 
Africa. Chang and colleagues (2003) also found Christians and blacks were more 
likely to use religion rather than other CAM therapies, in comparison with non-
Christians and non-blacks. Women (28.00%) in this study were almost as likely to 
use TCAMs as men (28.99%), whilst the Peltzer cohort (2008) in KwaZulu Natal, 
reported women more likely to use TCAMs then men.  
 
A comparison of the ARV and non-ARV patients suggested non-ARV patients were 
more likely to use TCAMs in the majority of the categories including gender, age, 
ethnicity, marital status and residence. However, the Pearson χ2 test applied to the 
results only showed a significant statistical difference in two categories, education 
and employment. Amongst the ARV patients, females (23.53%), those aged 56-65 
(50.00%), coloureds (39.13%), those who held traditional beliefs (37.50%), widowed 
(42.86%), highly educated (60.00%), those residing in suburbs (36.36%) and the 
self-employed patients (33.33%) used TCAMs the most. Amongst the non-ARV 
patients the males (39.39%), those aged above 65 (66.67%), coloureds (52.38%), 
participants who held both Christian and traditional beliefs (38.78%), the divorced 
(66.67%), the uneducated (42.86%), those residing in suburbs (60.00%) and the 
casually employed (60.00%) more commonly used TCAMs.  
 
With regards to socio-demographics, studies with larger sample sizes especially for 
the elderly, the cohabiting, those with no education as well as the highly educated 
and for the students are necessary for conclusive results. Further studies also need 
to be conducted to include a wider range of ethnic groups and religious faiths.  
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5.3.2. Health characteristics 
This section will give consideration to various patient health characteristics and the 
use of TCAMs. 
 
a) Period of HIV status awareness 
An analysis of the period of status awareness showed patients who were 
aware of their condition for one to three years used TCAMs the most, 34.29% 
(24; n=70), followed by those who were aware of their status, for less than 
three months, 33.33% (8; n=24). Those who had only been aware of their 
status for between three and 11 months used TCAMs the least, 6.45% (2; 
n=31), whilst 29.41% of patients who had been aware of their status for three 
to five years and for over five years used TCAMs. 
 
When the Pearson χ2 test was applied, a statistical difference between period 
of status awareness and the use of TCAMs amongst ARV and non-ARV 
patients was observed (χ2 = 9.62222; df = 3; P < 0.05). Amongst all the 
groups, TCAM use was more common in patients not on ARVs. The non-ARV 
patients aware of their status for less than three months, for three to five years 
and for over five years were much more likely to use TCAMs when compared 
with the ARV patients. Non-ARV patients aware for less than three months 
showed a 36.36% (8; n=22) likelihood of using TCAMs compared with 0.00% 
(0; n=2) of those on ARVs. TCAM use for those aware for three to five years 
was 43.76% (7; n=16) whilst that of ARV patients was almost half at 22.86% 
(8; n=35). That of those aware for over five years was 47.62% (10; n=21), 
compared with 21.28% (10; n=47) for those on ARVs. (Figure 5.15) 
 Figure 5.15: Use of TCAMs amongst ARV and non
period of status awareness 
 
The difference at less than three months may have been
counselling of patients being initiated on ARVs, though there were only two 
patients in this category. A
ARV patients between the one to three year
cases, due to a lack of ongoing counselling
noted that patients tend to continuously search for poss
paired with a lack of ongoing counselling, may possibly have been the reason 
for increased use of TCAMs b
the ARV patients.  
 
b) CD4 count 
Amongst the total HIV positive sample population (n=244), patients with a 
CD4 count of between 0
(71.43% (n=7)). In the other groups TC
33.33%. (Figure 5.16) 
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 Figure 5.16: Use of TCAMs in relation to CD4 count
 
A comparison of the ARV and non
ARVs were more likely to use TCAMs in all cases. A large difference was 
seen in the 0-49 group, in which 100.00% (4; n=4) of the non
used TCAMs compared with 33.33% (1; n=3) 
patients who did not know their CD4 count, none of the ARV patients used 
TCAMs, whilst 36.84% (7; n=19) non
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was applied (χ2 = 8.05530; d
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 Figure 5.17: CD4 count relationship to TCAM use amongst ARV and non
 
c) Personal opinion of health
Only one patient perceived their health as being “very poor” and did not use 
TCAMs. TCAM use appeared to decrease with an increasing positive 
perception of health status, 33.33% (5; n=15) patients who felt “poor”, 28.30% 
(15; n=53) who felt “fair”, 28.24% (48; n=170) who felt “good” and 20.00% (1; 
n=5) patients who felt “excellent”, used TCAMs. 
 
When comparing the use of TCAMs amongst ARV and non
Pearson χ2 test showed a significant statistical difference
2; P < 0.05). The use of TCAMs decreased from a poor to excellent 
perception of health status amongst the non
in the ARV patients. The non
when they perceived their 
38.46% (10; n=26) of those who described their health status as fair, and 
33.82% (23; n=68) of those who described it as good, used TCAMs. Patients 
who described themselves as feeling excellent amongst the AR
used TCAMs more commonly, 25.00% (1; n=4), compared with non
patients, 0.00% (0; n=1). (Figure 5.18)
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 Figure 5.18: Health relationship to TCAM use amongst ARV and non
 
d) HIV-related symptoms and medication adverse effects
All the patients experiencing nausea used TCAMs, 100% (n=7), followed by 
those who were vomiting, 45.45% (5; n=11). Of the patients who had lost their 
appetite 38.89% (7; n=18) used TCAMs, whilst those experiencing diarrhoea 
used TCAMs the least, 22.22% (2; n=
 
Although these are common HIV
common adverse effects associated with the use of ARVs. A
of TCAM use amongst ARV and non
the symptoms patients were experienc
or adverse effects as a result of their medication.
 
Patients on ARVs who were experiencing nausea used TCAMs the most, 
100% (7; n=7), whilst none of the non
Amongst the non-ARV patien
use TCAMs, 100% (3; n=3). According to all the participants, insomnia was a 
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 medication’ and this may possibly be due to inadequate counselling. Amongst 
the ARV patients, all three who complained of insomnia claimed not to be 
using TCAMs. Apart from the p
suggest that TCAM use is highest amongst those experiencing HIV
symptoms or adverse effects due to medication other than ARVs (Figure 
5.19).  
Figure 5.19: HIV related symptoms/medication adverse effects relationship 
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treatment. The Pearson χ2 test applied to the results indicated a statistical difference 
between ARV and non-ARV patients in the ‘period of status awareness’ and in the 
‘patient’s opinion of their personal health’. 
 
A study carried out by Peltzer and colleagues (2008) in KwaZulu Natal, showed 
patients used TCAMs for symptoms such as pain relief, immune supplementation, 
stress-relief and for the improvement of their general wellbeing. Dhalla and co-
workers (2006) reported objective symptoms such as rash, fever and diarrhoea to be 
associated with CAM use in British Colombia. The cohort also reported a significant 
relationship between CAM use and ARV adverse effects. Statistically significant 
associations of CAM use with peripheral neuropathy and gastrointestinal side effects 
have also been reported amongst ARV patients (Braitstein et al. 2001). The Chang 
cohort (2003) reported no significant relationships between CAM therapy and CD4 
count or viral load. Some studies have reported a delay in the progression of the 
disease and an improvement in the CD4 count with TCAM use (Ozsoy and Ernst 
1999). Another study showed a reduction in neurological, gastrointestinal, respiratory 
symptoms and sleep disturbances after using CAMs for a period of 12 weeks (Chang 
et al. 2003). 
 
5.3.3. Clinical management 
As indicated in Chapter 2, the Department of Health (2004) recommended regimens 
for ARV therapy included: 
 
• Regimen 1a: Stavudine + Lamivudine + Efavirenz 
• Regimen 1b: Stavudine + Lamivudine + Nevirapine 
• Regimen 1c: Zidovudine + Lamivudine + Efavirenz or Nevirapine 
• Regimen 1d: Tenofovir + Lamivudine + Efavirenz or Nevirapine 
• Regimen 2a: Zidovudine + Didanosine + Lopinavir/ritonavir 
• Regimen 2b: Tenofovir + Lamivudine +  Lopinavir/ritonavir 
• Regimen 2c: Zidovudine + Didanosine and double dose Lopinavir/ 
ritonavir 
 
As of 2010, these Department of Health guidelines have been changed as follows:  
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• Regimen 1a: Tenofovir + Lamivudine or Emtricitabine + Efavirenz or 
Nevirapine 
• Regimen 1b: Stavudine + Lamivudine + Efavirenz or Nevirapine 
• Regimen 1c: Zidovudine + Lamivudine + Efavirenz or Nevirapine 
• Regimen 2a: Tenofovir + Lamivudine or Emtricitabine + 
Lopinavir/Ritonavir 
• Regimen 2b: Zidovudine + Lamivudine + Lopinavir/Ritonavir 
  
Data collection for this study was carried out in 2009 during which time the former 
guidelines were still being implemented by the municipal ARV clinics, however, some 
newer regimens had already been initiated by patients at private treatment sites.  
 
Table 5.3 below shows the extent to which specific ARV regimens were used by the 
sample population. 
  
Table 5.3: Extent of use of specific ARVs 
ARV regimen No. of patients 
(n=138) 
Previous (2004) regimens  
• 1a 75 (54.35%) 
• 1b 20 (14.19%) 
• 1c 17 (12.32%) 
• 1d 7 (5.07%) 
• 2a 0 (0.00%) 
• 2b 1 (0.72%) 
• 2c 1 (0.72%) 
  
Current (2010) regimens  
• 1a 2 (1.45%) 
• 1b 0 (0.00%) 
• 1c 0 (0.00%) 
• 2a 6 (4.35%) 
• 2b 1 (0.72%) 
  
Regimen unknown to patient 8 (5.80%) 
  
 
As shown in table 5.3, nine (6.52%) patients were on the regimens of the newer 
Department of Health guidelines (2010), whilst eight (5.80%) patients did not know 
 the ARVs they were on. Amongst those on the first line regimen
guidelines, both (1.45%) patients were on tenofovir + emtricitabine + efavirenz. 
the second line regimens of the 2010 guideline
tenofovir + emtricitabine + lopinavir/ritonavir, whilst only one (0.72%) patient was on 
zidovudine + lamivudine + lopinavir/riton
 
This section will attempt to find a relationship between the clinical management of 
patients and their use of TCAMs.
 
a) TCAM use with specific ARVs
Only one participant was on regimen 2c of the previous guidelines, and this 
patient was using TCAMs. This is followed by those on the currently 
recommended regimens, 33.33% (3; n=9), and those on re
(6; n=20). Amongst patients on regimen 1c, 29.41% (5; n=17) were TCAM 
users. (Figure 5.20) 
Figure 5.20
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emtricitabine + lopinavir/ritonavir combination were using TCAMs, 50.00% (3; 
n=6). All the patients on the newer regimens were from the private sites. 
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treatment failure. According to the patients using TCAMs with the newer 
regimens, all of them used TCAMs throughout the period of switching 
regimens. Further studies would be necessary to investigate the likelihood of 
using TCAMs with the newer recommended regimens as the initiating 
therapy. The likelihood of using TCAMs with other newer regimens was found 
to be 0.00% (n=3).  
  
b) TCAM use with other conventional medicines 
Apart from ARV therapy, most of the participants were also using other 
conventional medicines. Medicines prescribed on a regular basis included co-
trimoxazole, multivitamins and vitamin B-complex. Co-trimoxazole + 
multivitamins and Co-trimoxazole + vitamin B-complex were usually given 
concomitantly, except for those patients with a CD4 count above 350 
cells/mm3, and those sensitive to co-trimoxazole. Above 350 cells/mm3, 
patients generally do not require co-trimoxazole prophylaxis as the immune 
system is strong enough to prevent opportunistic infections (Federal Ministry 
of Health 2006). 
 
A combined analysis of the ARV and non-ARV populations revealed no 
difference in the extent of TCAM use in patients prescribed other conventional 
medicines. Of those on multivitamins, 29.23% (19; n=65) used TCAMs, and 
similarly with vitamin B-complex, 28.47% (39; n=137), and co-trimoxazole, 
28.70% (33; n=115).  
 
A comparison of the ARV and non-ARV populations showed TCAM use in 
those not on ARVs was more common than patients on ARVs. In the non-
ARV group, 47.83% (11; n=23) patients used TCAMs with multivitamins, 
compared with 19.05% (8; n=42) of the ARV patients. Whilst 37.88% (25; 
n=66) non-ARV patients, and only 19.72% (14; n=71) ARV patients used 
TCAMs concomitantly with vitamin B-complex. Of the patients on co-
trimoxazole, 39.68% (25; n=63) non-ARV patients and 15.38% (8; n=52) ARV 
patients used TCAMs. (Figure 5.21) Although these results seem to 
complement the dissatisfaction shown by many non-ARV patients about 
conventional medicines prescribed by HCPs, the Pearson χ2 test showed no 
 significant statistical difference in TCAM use between the ARV and non
populations (χ2 = 2.01; d
 
Figure 5.21: Conventional medicine relationship to TCAM use amongst ARV 
 
c) Counselling by HCPs
An analysis of patient counselling with regards to self
total sample population (n=244) showed 184 (75.41%) patients were 
counselled by their HCPs, whilst 60 (24.59%) patients could not recall self
prescribing practices being mentio
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 Figure 5.22: Patient counselling with regards self
 
Interestingly, patients who were counselled against
used TCAMs just as commonly as those not counselled; 28.26% (52; n=184) 
and 28.33% (17; n=60), respectively. 
 
Comparing ARV and non
TCAMs less than patients who were on ARV treatment. A
were counselled, used TCAMs as much as those who were not counselled 
about using them, 22.86% (24; n=105) and 21.21% (7; n=33), respectively; 
whilst amongst non-ARV patients, 35.44% (28; n=79) of those who had been 
counselled used TCAMs, an
TCAMs. (Figure 5.23) These results are similar to those of TCAM use 
amongst the two populations i.e. 
(n=106) non-ARV patients.
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 Figure 5.23: Counselling relationship 
This shows the use of TCAMs 
as both categories of patients showed
conventional medicines, regardless of counselling. The Pearso
applied to the results showed no significant statistical difference in TCAM use 
amongst ARV and non
 
Overall, an analysis of the clinical management of the entire sample population 
showed no difference. A comparison of the ARV an
the non-ARV patients used TCAMs more often, in all cases. Amongst the patients 
not on ARVs, those prescribed multivitamins (47.83%) and those not counselled 
(37.04%) used TCAMs most commonly; whilst patients on ARV treatment wh
prescribed vitamin B-complex (19.72%) and those who were counselled (22.86%), 
used TCAMs the most. The differences that counselling made, amongst the same 
populations, were however very small. 
 
In the study conducted by Chang and colleagues (2003),
ARVs consulted their HCPs with regards 
Eisenberg group (1998) reported 40%, whilst Duggan and colleagues (2001) 
reported 43%. The KZN study reported up to 90% of the
therapies did not disclose TCAM use to their HCPs (Peltzer 
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In order to optimise patient care, HCPs should be made aware of the potentially 
hazardous effects, including drug interactions and adverse effects, associated with 
the use of TCAMs (Furler et al. 2003) Extensive clinical trials of the commonly used 
TCAMs need to be conducted in order to weigh the risk benefit ratio of TCAM use in 
HIV, with or without ARVs. Studies with larger sample sizes of those on the currently 
recommended ARV regimens, as well as those on the second line regimens of the 
previous guidelines would be necessary for conclusive results in those populations.  
 
 
5.3.4. Management of HIV with TCAMs 
As mentioned previously in the beginning of this section, a total of 69 patients 
(28.28%; n=244) were using TCAMs, of which 31 patients (22.46%; n=138) were on 
ARV treatment, whilst 38 patients (35.85%; n=106) were not. This section will 
discuss non-conventional medicine use, by the study sample in the management of 
HIV. 
 
a) Use of specific TCAMs 
The study revealed a wide variety of TCAMs being used. Of the sample 
population who used TCAMs (n=69), 28.99% (20) of them used garlic. 
Patients using “muthi” from traditional healers, and those on African potato 
each made up 11.59% (8) of the TCAM population. Some of the respondents 
could not remember the name of the TCAMs they were on, 18.84% (13). 
Table 5.4 below shows the wide variety of TCAMs, and the extent, in 
descending order, to which they were used by the total TCAM population. The 
table also shows the extent to which TCAMs were used by the ARV and non-
ARV populations.  
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Table 5.4: Types of TCAMs and extent of use  
TCAM Total patients 
using TCAMs 
(n=69) 
ARV patients using 
TCAMs (n=31) 
Non-ARV patients 
using TCAMs 
(n=38) 
Garlic 20 (28.99%) 8 (25.81%) 12 (31.58%) 
Name unknown 15 (21.74%) 5 (16.13%) 10 (26.32%) 
Muthi 8 (11.59%) 6 (19.35%) 2 (5.26%) 
African potato 8 (11.59%) 4 (12.90%) 4 (10.53%) 
Ginger 5 (7.25%) 1 (3.23%) 4 (10.53%) 
Magogotha Carniboost
®
 4 (5.80%) 1 (3.23%) 3 (7.89%) 
StamettaTM
 
4 (5.80%) 1 (3.23%) 3 (7.89%) 
Cell food® 4 (5.80%) 4 (12.90%) 0 (0.00%) 
Spirulina 3 (4.35%) 2 (6.45%) 1 (2.63%) 
Swiss Garde Products 3 (4.35%) 0 (0.00%) 3 (7.89%) 
Moducare® 3 (4.35%) 1 (3.23%) 2 (5.26%) 
Daggabossie 3 (4.35%) 0 (0.00%) 3 (7.89%) 
Aloe Vera 2 (2.90%) 0 (0.00%) 2 (5.26%) 
Immunadue 2 (2.90%) 1 (3.23%) 1 (2.63%) 
Sutherlandia 2 (2.90%) 1 (3.23%) 1 (2.63%) 
Viral guard 1 (1.45%) 0 (0.00%) 1 (2.63%) 
Procydin 1 (1.45%) 0 (0.00%) 1 (2.63%) 
Avocado seed extract 1 (1.45%) 0 (0.00%) 1 (2.63%) 
Carotenoids 1 (1.45%) 1 (3.23%) 0 (0.00%) 
Herbal Life Products 1 (1.45%) 1 (3.23%) 0 (0.00%) 
Chinese medicine 1 (1.45%) 1 (3.23%) 0 (0.00%) 
Homeopathic medicine 1 (1.45%) 1 (3.23%) 0 (0.00%) 
Izifozonke 1 (1.45%) 1 (3.23%) 0 (0.00%) 
    
 
Figure 5.24 shows a comparison of the specific TCAMs used by the ARV and 
non-ARV populations. The Pearson χ2 test showed no significant statistical 
difference between these populations.  
 
Patients were further asked if they knew anyone using TCAMs for the 
management of HIV. Of the entire sample population (n=244), up to 84.02% 
(n=205) patients knew of at least one person who was using TCAMs, with the 
highest number of TCAM users known to a single participant being six. A total 
of 371 individuals were reported to be using TCAMs, out of which 31.15% 
(n=76) of the participants believed the known users were not visiting clinics for 
conventional treatment. 
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Although muthi was mentioned very often, many of the participants were not 
aware of the names of the specific TCAMs used by others. Three participants 
mentioned a church which was involved in HIV management. This particular 
church reportedly advised patients on ARVs to discontinue their conventional 
treatment. They were then given some ‘special’ water which the church 
claimed to be a cure, so long as the patients put their trust in God.   
 
  
  
Figure 5.24: Types of TCAMs used by the ARV 
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 b) Reasons for TCAM use
Of the total sample population using TCAMs (n=69), the majority, 
94.20% (65), believed the non
improved their health. Some expressed dissatisfaction wi
conventional medicines as the reason for using TCAMs, 43.48% (30), 
whilst 27.54% (19) of patients said they used TCAMs due to family 
traditions/cultures. A further 11.59% (8) used TCAMs because they 
believed they were more natural compared to convention
10.14% (7) believed non
adverse effects associated with conventional medicines. Other reasons 
cited for using TCAMs included: more personal control of their health 
with TCAMs, curiosity, and belief that T
(Figure 5.25) 
 
Figure 5.25
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-
, and 
 only 16.13% (5; n=31
conventional medicines.
and none of the non
associated with their conventional medicines. (Figure 5.26)
Figure 5.26: A comparison of the reasons for using TCAMs amongst 
ARV 
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Aloe Vera was used for stomach cramps and diarrhoea, and also 
applied topically for skin rashes. Magogotha Carniboost® was used for 
body pains, joint pains, TB, to boost the immune system, to counteract 
ARV adverse effects and for blood pressure. Stametta® was used for 
flu and cough, mood elevation, to boost the immune system, for 
lethargy, to improve digestion and overcome constipation. Spirulina 
was used as a supplement, as patients believed it worked like 
conventional multivitamins, but was more natural. Patients on Swiss 
Garde products, African Potato and Moducare® used them for boosting 
the immune system. Daggabosie was mainly used for mood elevation 
whilst Cell Food® was used for energy, to detoxify the body, to prevent 
infections and for TB.   
 
Some patients believed they were bewitched and turned to the 
sangoma for healing, whilst others used muthi to alleviate side effects 
associated with ARVs. One patient, who had experienced nausea and 
vomiting since ARVs were initiated, claimed to have complained to his 
HCPs repeatedly, for a period of one year, but to no avail. A sangoma 
approached for the same symptoms prepared a concoction which 
helped alleviate the adverse effects completely, whilst he continued his 
ARV treatment. The sangoma advised the patient to return when he 
had enough money for muthi that would apparently be better than 
ARVs, and possibly cure him. Convinced by the first treatment, the 
patient was looking forward to raising enough money for the so-called 
‘cure’, which was quoted at R2200 by the sangoma. With regards to 
Muthi as a cure, up to six patients mentioned having heard of a 
sangoma in Transkei who was said to be ‘very good’ and claimed to 
have cured many with HIV. Most of the patients did not know the price, 
only knowing this ‘cure’ was too much for them to afford, with one 
patient quoting it at approximately R5000.  
 
One patient, at the time of the interview, had been planning on 
attending a Christian workshop in Johannesburg, which claimed to cure 
the patients by the end of its two week course. 
  
c) Patient responses
Of the TCAM population 
self-prescribing (n=32), the majority, 62.50% (20) 
their HCPs they were not using them. 
 
Non-ARV patients seem more likely to deny TCAM use when asked by 
HCPs, 83.33% (15; n=18), than patients on ARVs, 
(Figure 5.27)  
Figure 5.27: A comparison of the extent to which patients d
prescribing, when 
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e) Drug/TCAM interaction awareness
An analysis of the patient awareness of drug/TCAM interactions 
revealed that the majority of TCAM users, 88.41% (61; n=69), were not 
aware of any such interactions. 
 
Of those who were not aware of any interactions, 92.11% (35; n=38) 
were non-ARV patients 
Some of those who were aware, 16.13% (5; n=31) ARV patients, and 
7.89% (3; n=38) non
drugs and TCAMs are synergistic. (Figure 5.29)
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 Figure 5.29: A comparison of 
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f) Belief in HIV cure 
Amongst the total HIV positive sample population using TCAMs (n=69), 
18.84% (13) of patients believed TCAMs could actually cure them, 
however none of them believed the TCAM
(Figure 5.30). These patients were either, still in search of a cure, or 
did not have the funds to afford one yet. 
Figure 5.30: Patients believing in the existence of a 
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In summary: 
• A wide variety of TCAMs were used by the sample population, the 
most common one being garlic (28.99%). This however cannot be 
generalised as the majority of the participants in the study sample 
(n=244) claimed to know individuals who were using muthi more 
commonly for HIV, and many of these patients did not seek medical 
attention from clinics.  
• Various reasons for using TCAMs were identified, the most common 
reason being for the improvement of health (94.20%).  
• Non-ARV patients were shown to be statistically more dissatisfied with 
conventional medicines (65.79%), than patients who were using ARVs.  
• All the patients who used TCAMs to counteract adverse effects of 
conventional medicines were on ARVs (22.58%).  
• A high percentage of patients using TCAMs admitted to denying their 
use, when asked by their HCPs (62.50%), the most common cited 
reason for this was a fear of being prevented from using them 
(80.00%). 
• Many patients using TCAMs were not aware of drug/TCAM interactions 
(88.41%), and those who were aware believed in drug/TCAM 
synergism.  
• Up to 18.84% of the TCAM population actually believed in the 
existence of a cure for HIV, ‘cures’ being available either from 
traditional healers or from Christian churches. 
 
The study in KwaZulu Natal by Peltzer and colleagues (2008) reported that up 
to 90% of those using herbal therapies did not admit it to their HCPs. 
Furthermore the study showed patients on TCAMs were significantly less 
satisfied with their HCPs. Only 4.1% of the participants believed HIV could be 
managed solely with TCAMs. The Canadian study by Furler and colleagues 
(2003) reported the main reason for TCAM being general wellbeing. Other 
reasons given were healing, spiritualism, stress, pain and relaxation. Up to 
9% of their population believed HIV could be managed with TCAMs alone. 
The study in British Colombia by Dhalla and colleagues (2006) cited the main 
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reasons for TCAM use as energy, a supplement for dietary intake and for 
boosting the immune system. The KZN study reported the use of cannabis for 
stress relief (85.7%), for relaxation (23.5%) and for pain relief (17.6%) (Peltzer 
et al. 2008).  
 
Further studies need to be carried out to determine the number of patients 
seeking help from TCAM practitioners alone, and the types of TCAMs they 
are using. Extensive clinical trials of the commonly used TCAMs need to be 
conducted in order to weigh the risk to benefit ratio of TCAM use in HIV, with 
or without ARVs. 
 
5.4. HCP INTERVIEWS 
As previously stated in section 5.2.2, a total of 29 HCPs, including 7 doctors 
and 22 nurses, were interviewed from 11 clinics of the Nelson Mandela Bay 
Municipality. These HCPs came from both the public and private sectors.  
 
a) HCPs recommending TCAMs 
Of the 11 sites from which HCPs were interviewed, one private ARV 
clinic was actually involved in the management of HIV with TCAMs as 
standard treatment, prior to ARV therapy. 
 
Of the total HCP population (n=29), 75.86% (22) did not recommend 
the use of TCAMs in HIV, prior to or during ARV therapy, whilst 24.14% 
(7) recommended use, but only prior to ARV treatment being initiated 
(Figure 5.31).  
 Figure 5.31: Extent to which TCAMs are recommended by HCPs
Two doctors and two of the nurses w
from the clinic that used TCAMs as 
doctors (n=5), and 
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Figure 5.32: Comparison of TCAM recommendation amongst doctors 
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 approximately 200 patients who were not on ARVs, of these 
approximately 80% were reported to be on 
remaining 20% on 
improvement in the general wellbeing of patients, together with a 
slower decline in CD4 count with herbal therapy. 
reportedly better tolerated by patients than 
 
The nurses from other clinics who recommended TCAMs in their 
personal capacity, but not as a standard clinical practice at their 
practice sites, recommended
(1), garlic, 5% (1), 
and Hypericum perforatum 
recommended TCAM use prior to ARV therapy.
 
c) HCP awareness of 
A total of 55.17% HCPs from the total HCP sample (n=29) were aware 
of patients using TCAMs, whilst 44.83% (13) did not know of any self
prescribing practices (Figure 5.33).
Figure 5.33: Extent to which HCPs are aware of TCAM use amongst HIV 
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• The belief that some herbs can reverse the progressive immune 
deficiency caused by HIV, and potentially restore specific 
immune responses lost with chronic infection.  
 
There was also the opinion expressed that, for reasons of losing profits, 
pharmaceutical companies prevented large conclusive studies that could 
potentially prove the efficacy of numerous TCAMs. 
 
Conversely, other HCPs did not recommend TCAMs, suggesting that there 
was no significant in vivo evidence to prove the safety and efficacy of these 
products in humans. Some also believed TCAMs may possibly be helpful for 
short periods of time, but since there was no substantial evidence to prove 
their safety when used for a longer period, they should rather be reserved till 
full clinical trials have been conducted. The effects of some TCAMs on the 
liver, such as the near-complete inhibitory effect of Sutherlandia on the 
CYP3A4 enzymes (Mill et al. 2005), made some HCPs reluctant to use them, 
especially with ARVs. Also, since the antibacterial and antiviral effects of 
some TCAMs have now been proven, some HCPs felt proper studies should 
now be conducted to establish the minimum and maximum periods of therapy, 
so as to avoid the development of resistance or toxicity. In so doing, the 
efficacy of TCAMs would be protected from bacterial or viral resistance, 
thereby making them available for future use as possible alternatives to 
ARVs. Other HCPs simply did not believe TCAMs were helpful, and those that 
were widely used by patients were the result of clever marketing strategies.   
 
A doctor from an ARV site, who expressed very strong opinions against the 
use of TCAMs, also expressed dissatisfaction with the government’s 
recommendation of starting ARVs at a CD4 count of 200 cells/mm3. He 
suggested that the initiation of ARVs should be done at least by a CD4 count 
of 350 cells/mm3, regardless of the clinical stage of the condition. His analogy 
was that of a fire in a building. “If everything inside the building is severely 
burnt out, there is no point in putting out the fire, as the building will have to be 
demolished in any case”. Similarly, according to the HCP, delaying treatment 
to a later stage would damage the patients system to an extent that it would 
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be irreversible. He was also not satisfied with some of the ARVs 
recommended in South Africa. Even though these drugs could potentially 
reduce viral load to undetectable levels, he believed long term use had drug-
related complications on organs such as the liver and the bone marrow, just 
as life threatening as the HIV condition itself, if not worse. Furthermore, he did 
not believe there was any TCAM available for the management of HIV. 
According to him, the perception amongst some people, including HCPs, 
about an improved general well being of those taking TCAMs was wrong. This 
misperception was first of all linked to individual HIV set points, and secondly 
because of biased marketing strategies. The viral load of an individual usually 
increases rapidly immediately after infection, and eventually stabilises when 
HIV antibodies have been developed. The set point, which differs between 
individuals, is the point at which the viral load remains relatively stable. The 
higher the set point, the faster the progression to full-blown AIDS (Geskus et 
al. 2007). According to the HCP, patients with a slower decline in CD4 count 
simply had a lower set point, therefore the slow decline could not necessarily 
be attributed to TCAMs. He suggested that, “For marketing purposes, only 
those patients with a slower decline in CD4 count (with a low set point) are 
reported, whilst those with a quick progression to AIDS (with a high set point), 
undergoing the same TCAM therapy, were ignored.” 
 
5.5. TCAM PRACTITIONER/PROVIDER (TCAMP) INTERVIEWS  
A total of 30 TCAMPs practicing in the Nelson Mandela Bay Municipality, 
were interviewed. As mentioned earlier (section 5.2.3), two (6.67%) of these 
were naturopaths; 12 (40.0%) herbalists; seven (23.33%) traditional healers; 
one (3.33%) homeopath; two (6.67%) religious practitioners; one (3.33%) 
nutritional counsellor; and five (16.67%) shop owners that stocked TCAMs.  
 
The TCAMPs were unable to specify the number of patients seeking TCAM 
therapy for HIV, as they did not keep a written record of the patients that 
visited them. It was also noted that many of the traditional healers and 
herbalists in the Nelson Mandela Bay Municipality were foreigners.  
 
 
 a) TCAMPs providing TCAMs
Of the total TCAMP sample population interviewed (n=30), 90.00% (27) 
provided TCAMs for HIV, whilst 10.00% (3) did not (Figure 5.35). 
Figure 5.35: Extent to which TCAMPs provide TCAMs for HIV (n=30)
 
b) TCAMPs recommending TCAMs
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Both naturopaths interviewed recommended the use of TCAMs, as did 
91.67% (11; n=12) of the herbalists and 85.71% (6; n=7) of the 
traditional healers. Only 25.00% (3; n=12) of the herbalists and 28.57% 
(2; n=7) of the traditional healers were South African, with the rest 
coming from Tanzania, Uganda, Zanzibar, Kenya, Burundi and 
Zimbabwe. The majority of the foreign TCAMPs claimed to be using 
herbs sourced mainly from East Africa. All the interviewed herbalists 
from South Africa had well-established businesses and stocked only 
commercial herbal products. The herbalists stocked herbs which they 
had personally packed, and like the traditional healers, either operated 
from home or from small office buildings. 
 
The shop owners, 16.67% (5; n=30), were selected from various areas 
of the City. These businessmen assumed that the majority of their 
customers purchasing TCAMs did so for the management of HIV, 
although very few of their customers told the shop owners what they 
were using the TCAMs for. Assumptions made by the businessmen 
were based on both, admission of some of their customers about their 
HIV status, and the evidence of symptoms which they suspected were 
HIV-related. The shop owners’ interpretation of HIV symptoms included 
coughing, lethargic, malnourished, thin and depressed looking 
appearance. 
 
c) Concomitant use of Western medicines with prescribed TCAMs 
Amongst the total TCAMP sample population that recommended 
TCAMs (n=22), 63.64% (14) asked patients if they were using 
conventional medicines, whilst 36.36% (8) did not (Figure 5.37). 
 Figure 5.37: Extent to which TCAMPs ask about the use of conventional 
Of the same group, 36.36% (8) were aware of drug/TCAM interactions, 
whilst 63.64% (14) were not aware of a
compromise, or even facilitate their treatment recommendations 
(Figure 5.38). 
Figure 5.38: Extent to which TCAMPs are aware of drug/TCAM 
An analysis of the extent to which TCAMPs advised patients to 
discontinue conventional treatment 
actually did so, whilst 95.45% (21; n=22) did not advise such practice 
(Figure 5.39). 
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d) Recommendations of specific TCAMPs
Of the six traditional healers
revealed the ingredients they were using. The majority, 66.67% (4), 
asked their patients if they were usin
33.33% (2) were aware of drug/TCAM interactions. However, none of 
them advised their patients to stop their conventional treatment. 
 
Of the 11 herbalists
recommended the use of 
(1) Echinacea; 18.18% (2) 
(2) Garlic; 9.09% (1)
9.09% (1) Ginger and 72.72% (8) made up a concoction with a mixture 
of various herbs according to the symptoms the patients presented 
with. All those making concoctions were traditional herbalists. Those 
who named the herbs were commercial herbalists who also 
recommended other products such as those manufactured by Herbal 
Life, Golden Neo-life Diamite (GNLD) and Swiss Garde. Amongst the 
herbalists who recommended TCAMs (n=11), 63.64% (7) asked their 
patients if they were using any conventional medicines, and 36.36% (4) 
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were aware of drug/TCAM interactions with their treatment. Only 9.09% 
(1) actually advised patients to stop taking conventional medicines.  
 
Amongst the two claiming to be naturopaths, neither disclosed the 
names of the TCAMs they had to offer for the management of HIV. 
One of them, from Sudan, who called himself ‘the natural medicine 
practitioner’, gave his patients individualised medicines, according to 
their presenting symptoms. His medicines were prescribed for 
symptoms such as nausea, vomiting, diarrhoea, rashes and lost 
appetite, which were associated with HIV. Neither of the two asked 
their patients about the use of conventional medicines, nor were they 
aware of any drug/TCAM interactions that would compromise their 
prescribed therapy. Both claimed to have no adverse effects with their 
prescribed treatment, as their treatment was ‘completely natural’. 
 
The homeopath recommended TCAMs to HIV positive patients, but 
not homeopathic medicines. The patients were prescribed the 
commercialised herbal product, Sutherlandia frutescens. The TCAMP 
was aware of potential drug/TCAM interactions, therefore all patients 
seeking treatment were asked about the use of conventional treatment. 
Only those patients not on ARVs were prescribed herbal therapy. The 
homeopath worked in conjunction with a private ARV clinic, and 
claimed to have noted a positive effect on the general wellbeing of 
patients who were using his recommended treatment. He also 
recommended life-style management including faith healing, 
meditation, yoga, reiki and acupuncture.  
 
The TCAMs recommended by the nutritional counsellor were aimed 
at bridging the nutritional gap created by the condition, and to help 
minimise HIV symptoms. If TCAMs or conventional medicines were 
self-prescribed, and the counsellor was unaware of the consequences 
of using such medicines, the patients would be advised to seek 
medical advice from a doctor. With regards to the recommended 
TCAMs, the counsellor did not believe there were any drug/TCAM 
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interactions or adverse effects. The counsellor claimed, “The 
prescribed supplements were all sourced from the normal human food 
chain that was not conflicting with conventional medication”, and that 
“the ingredients were pure, unpolluted and organically grown”. 
Recommended TCAMs included Phyto-nutrients, Carotenoid comlplex, 
Flavonoid complex, Cruciferous Plus, multivitamin supplements, 
mineral supplements, vitamin E and garlic. The counsellor also 
recommended protein shakes that were claimed to be very effective. 
 
The Muslim religious TCAMP believed there were treatments for all 
ailments. She was influenced by the teachings of the Prophet of Allah, 
Muhammad Sallalaahu Alaihi Wasallam. She cited a conversation of 
the Prophet in which Bedouins had come to ask if they could seek 
medicine for the treatment of diseases. The Prophet said, “Yes, Oh 
slaves of Allah, seek medicine, for Allah has not created a disease 
except that He has also created its cure, except for one illness.” The 
Bedouins asked, “And what disease is that?” The Prophet replied, “Old 
age.” Because of this conversation, the TCAMP believed with certainty, 
that there was a cure for HIV, and furthermore that the cure would be 
found in nature. The TCAMP treated the sick by encouraging them and 
strengthening their determination, quoting a saying of the Prophet, 
“When you visit a sick person, say good words to him for the Sake of 
Allah, although that does not prevent any harm, it still brings relief to 
the patient’s heart.” The TCAMP would then place her right hand on 
the sick patient and pray, “Oh Allah, Lord of mankind! Do away with the 
complaint and bring about the cure. You alone bring the cure, and 
there is no cure except Your cure, a cure that does not leave illness.” 
All patients, whether HIV positive or not, were asked if they were on 
any other medication. Those on TCAMs were either advised to 
continue or stop, according to the TCAMPs recommended treatments. 
Those on conventional medicines were advised to take the medicines 
at different times. Based on the saying of the Prophet, “Make use of 
two cures, honey and Quran”, honey was widely recommended for a 
variety of conditions. The Prophet recommended honey for physical 
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health, whilst the Quran was recommended for spiritual health. 
According to the TCAMP, in cases of HIV, honey can wash away 
harmful substances collected in the veins and intestines, and can be 
useful in cases of diarrhoea. It also helps to cleanse the liver and the 
chest. Honey was said to have no adverse effects except for those 
‘suffering from bile’, who were advised to take it with vinegar to 
neutralise the potential harm. Lemon grass was recommended for 
nausea, black seed for common colds and for various other conditions, 
and Aloe Vera was given to patients for mouth sores and depression. 
Musk, when inhaled or drunk, was said to bring comfort and joy to the 
heart and to strengthen the inner organs. The TCAMP also 
recommended ‘cupping’ for the extraction of ‘septic blood’. Cupping is 
a process by which small amounts of blood are drawn from specific 
areas of the body (Chishti 1991). The TCAMP also recommended male 
circumcision for the prevention of HIV infection during sexual 
intercourse and advised, by all means, to avoid anal sex “due to the 
extremely toxic microbes in the human faeces”.  
 
e) TCAMPs not providing TCAMs for HIV 
Of the TCAMPs not recommending TCAMs (n=3), one traditional 
healer, originally from Zanzibar, claimed to specialise in a variety of 
sexually-related problems, except HIV. The healer claimed to know of 
non-conventional medicines that could help alleviate HIV symptoms. 
However, the herb was difficult to access as it was only found in very 
remote areas of Tanzania.  
 
Another TCAMP, a herbalist who was himself HIV-positive, did not 
believe there were any TCAMs available for the management of HIV, 
and conventional treatment was necessary. The herbalist, originally 
from Uganda, advised his HIV-positive patients about eating healthy 
and encouraged them to seek conventional treatment. He also advised 
the patients to avoid sexual intercourse as much as possible as 
“intercourse takes up too much energyW energy that they need to fight 
HIV”.  
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A Christian pastor, introduced to the researcher by an HIV positive 
participant, believed there was healing in prayer alone. He believed 
there was no need for conventional or herbal medicines for HIV. Those 
confiding in him were however, not advised to stop conventional 
medicines, as he believed their faith in God was too weak. He blamed 
HCPs for brain washing people into believing that HIV was incurable.  
 
Overall, the interviews with the TCAMPs and patients showed that patients 
by-and-large seek TCAM therapies not only from TCAM practitioners, but also 
sought to buy them in shops where no advice or counsel was available. There 
was a wide variety of TCAMPs available for the patients to choose from. They 
were apparently more easily accessible and more approachable than HCPs. 
TCAMPs seem to spend much more time with their patients, and tend to take 
a broader interest in the patients beyond just treating their condition. The 
majority of the TCAMPs were not aware of any drug/TCAM interactions, and 
some TCAMPs actually advised their patients to discontinue conventional 
treatment (4.55%). 
 
Further studies need to be carried out with larger sample sizes of specific 
groups of TCAMPs. The impact of TCAMs sold in general dealer stores, in 
response to high demand for them, should also be investigated.   
 
In Uganda, there is one doctor per 20,000 people, compared with one 
traditional health practitioner per 200-400 people. Successful partnerships 
have been created between HCPs and traditional health practitioners in order 
to lower the rate of HIV infection, and these collaborations have proven to be 
effective. However, these programmes aim to “educate” these TCAM 
practitioners, whilst genuine information sharing remains to be a challenge. 
(Bodeker et al. 2006) 
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Chapter 6 
CONCLUSION 
 
In Africa, TCAM practitioners seem more easily accessible and approachable 
than HCPs, not only because they are widely available, but also because they 
provide a more holistic approach to health care (Homsy et al. 2004). 
Therefore TCAM use in HIV seems inevitable. HCPs need to use a similar 
approach to health care in order to gain the trust of patients. An open dialogue 
with patients may reveal issues that are not being considered by HCPs; 
issues that could improve patient involvement in the decision making process. 
For such a dialogue, patients need to be routinely counselled, on each clinical 
visit, with regards TCAM use, whether on ARVs or not, and HCPs need to 
recognise that patients may seek treatment from other sources.  
 
In South Africa, TCAMs do not undergo the rigorous registration processes 
that western medicines require. Due to insufficient clinical evidence regarding 
TCAMs available for purchase, pharmacokinetic and pharmacodynamic 
characteristics of the majority of these TCAMs are unknown. The safety, 
efficacy and possible drug/TCAM or even TCAM/TCAM interactions have not 
been established. Studies have shown some TCAMs could potentially be 
hazardous to the health of patients who are also on conventional treatment 
due to possible drug/TCAM interactions (Harnett 2004). Their use may also 
be harmful to those not being treated conventionally, as some TCAMs may be 
more detrimental than beneficial to the HIV state (Terreblanche 2003). For 
optimal therapeutic outcomes, further clinical studies need to be carried out to 
establish the possible risks, benefits and interactions of TCAMs commonly 
used in HIV, prior to and during conventional management. Only then will 
HCPs be in a better position to advise patients on which aspects of TCAMs 
can be safely combined with their conventional treatment. Clinical studies 
should be carried out on those TCAMs that are commercially available for use 
in HIV, since many of these locally manufactured products are those with an 
indigenous history, and traditionally recommended.  It is also important for 
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government to make amends to the legislation, to provide stringent 
registration processes for TCAMs, thereby preventing the registration of 
products without thorough clinical trials. 
 
Close partnerships between HCPs and TCAM practitioners, and collaboration 
with clinical studies of their prescribed treatments, is imperative. Such 
collaborations would not only allow both parties to make evidence-based 
decisions, but may also provide alternatives or additional therapies to the 
limited variety of ARVs, which have a high adverse-effect profile and a 
growing viral resistance. However, such partnerships may only be possible if 
both parties are aware of the problems at hand, and are willing to work 
together. Although a partnership in many African countries has been 
successful, this is only a one sided partnership in which the health care 
profession provides the information, and the TCAM practitioner is expected to 
‘obey’ (Bodeker et al. 2006). This kind of partnership lacks ‘information 
sharing’, which is vital for acceptance, acknowledgement and respect 
between the two parties.  
 
The primary aim of this study was to determine the prevalence of traditional, 
complementary and alternative medicine use in HIV positive patients, prior to 
and during ARV treatment. 
 
The study showed that TCAMs are commonly used by HIV-positive patients 
whilst on ARV treatment, as well as by those on conventional medicines other 
than ARVs. These medicines are also commonly used by patients who are 
HIV-positive, but not wanting conventional treatment.  
 
The study also showed that there is a wide variety and numerous TCAM 
practitioners, supplying TCAMs to patients. A large majority of these 
recommend TCAMs to patients for HIV, and for symptoms associated with 
HIV. Many of the practitioners recommend these medicines to be used 
concomitantly with conventional treatment, though a few only recommend 
them prior to ARVs. There are also TCAM practitioners who do not 
recommend concomitant use, and advise discontinuation of conventional 
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medicines. Furthermore, due to a high demand, numerous shops as well as 
pharmacies supply TCAMs to patients, without necessarily actively 
recommending them.  
 
Despite insufficient clinical evidence, some health care practitioners 
recommend TCAMs in HIV, based on anecdotal and in vitro evidence. Some 
of these practitioners prescribe specific TCAMs with a standard clinical 
protocol, whilst others recommend them on a more personal basis. The 
majority of these HCPs recommend TCAMs only prior to ARV treatment. 
 
A number of limitations to the study have to be acknowledged: 
• Since patient files were not accessible, the actual clinical management 
and the progression of the condition could not be determined. Patients, 
at times - seemed uncertain and therefore the information provided 
may not have been completely reliable. 
• Even though a statement of confidentiality was signed by the 
researcher, some patients still appeared to be uncomfortable and may 
not have admitted to using TCAMs. This may also have been 
exacerbated by the shortage of interaction time, as well as cultural 
differences between the patients and the researcher.  
• Since translators were not available in all study sites, the majority of 
the patients who participated in the study were conversant in the 
English language, and many who were not, could not be included in the 
study. This may have resulted in an element of bias in the reported 
results. 
• Since the study was carried out in a clinical setting, patients seeking 
help from TCAMPs alone were not included. The results may therefore 
only be generalised to those seeking help from HCPs, and not the 
general population. 
• Many patients who acknowledged the use of TCAMs could not 
remember the names of the specific products they were using, 
therefore certain TCAMs being used by the sample population may not 
have been reported. 
131 
 
 
• The Department of Health’s recommended ARV regimens changed 
after the data collection had been completed. Trends in TCAM use may 
also have changed with the newer regimens. 
• Even though the HCP-interview questionnaire was given to the HCP-
participants prior to the interview, very few had actually perused it prior 
to the interview. Therefore statistical information provided often only 
approximations. 
• TCAMPs were not able to specify the number of HIV-positive patients 
seeking help from them, as keeping records was not common practice. 
The true extent of TCAMP prescribing in the general population could 
therefore not be determined.      
 
This study suggests that the following further investigations would be 
warranted: 
• Patient socio-demographics: studies with larger sample sizes 
especially for the elderly, the cohabiting, those with no education as 
well as the highly educated and for the students. Also studies with a 
wider range of ethnic groups and religious faiths.  
• Patient clinical management: studies with larger sample sizes of those 
on the currently recommended ARV regimens, as well as those on the 
second line regimens of the previous guidelines.  
• TCAM management: studies to determine the number of patients 
seeking help from TCAM practitioners alone, and the types of TCAMs 
they are using. Extensive clinical trials of the commonly used TCAMs 
should be conducted, with or without ARVs.  
• TCAM practitioners: studies with larger sample sizes of specific groups 
of TCAMPs, and the impact of TCAMs sold in pharmacies and general 
dealer stores should be investigated. 
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Appendix 1a 
A survey investigating the use of Traditional, Complementary and  
Alternative therapy (TCAM) among adult HIV-infected patients  
HCP interview questionnaire 
Site No.   
Study 
No.   Date: ___________ 
         1) HCP interviewed (tick where appropriate): 
Pharmacist   
     
Doctor   Nurse   
         2) Approximate total number of patients attending clinic:____________ 
3) Approximate number of HIV-positive patients: ___________ 
4) Approximate number of patients not yet eligible for ARV treatment:___________ 
5) Predominant reasons for lack of eligibility (tick where appropriate):  
         CD4 count still high   
Intensive TB 
treatment   
Compliance   
other   Reason: ________________________ 
________________________ 
________________________ 
6) Are you involved in the prescribing of medication? Yes / No 
7) Are you aware of patients self-prescribing medication? Yes / No 
8) If you answered 'Yes' to questions (6) and/or (7), please complete the following table: 
      Approximate No. of patients   
  
Prescribed by: (Simply tick if number unknown)   
        TCAM         
  Self HCP 
Practitione
r Prior to With With   
  
 
 
 
 
 
 ARVs ARVs TCAM   
TCAM/Medication     (specify)       Comments 
Co-trimoxazole               
Fluconazole                 
Multivitamins                 
Vitamin E                 
Probiotics                 
Other (Specify):               
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9) Do you recommend the use of TCAM in HIV infected patients?  Yes / No 
10) Do you know of any HIV infected patients that self-prescribe TCAM?  Yes / No 
11) If you answered 'yes' to questions (9) and/or (10), please complete the following tables concerning 
TCAM prescribing, for the past 6 months: 
  
Precribed by 
Approx. No. of 
patients*   
        TCAM     
Comment on the 
extent to 
    Self HCP 
Practition
er Prior to With 
which use is disclosed 
by 
TCAM 
 
 
 
 
 
 ARVs ARVs patient to HCP 
        (specify)         
Herbal:                  
Sutherlandia               
Lobostemon                 
Echinacea               
African potato 
(Hypoxis)               
St. Johns Wort               
Ginseng                 
Garlic               
Ayurvedic medicine               
Chinese medicine               
Other (please 
specify):               
                
                  
                  
Lifestyle:                 
Homeopathic               
Prayer/ faith healing               
Meditation/ 
Visualization               
Yoga                 
Exercise               
Reiki                 
Acupuncture               
Massage                 
Chiropractic therapies               
Other (please 
specify):               
                
                  
                  
*If approximate number of patients is unknown, simply tick to show awareness of specific TCAM use 
12) Are HIV infected patients counselled about the use of TCAM: 
Prior to ARV therapy? Yes / No 
During ARV therapy? Yes / No 
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13) Your opinion on the use of specific TCAMs in HIV prior to and during ARV therapy 
                  
        
            
            
14) Further comments 
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Appendix 1b 
A survey investigating the use of Traditional, Complementary and  
Alternative therapy (TCAM) among adult HIV-infected patients  
TCAM practitioner interview questionnaire 
Site No.   Study No.   Date:     
1) Prescriber interviewed (tick where appropriate): 
Naturopath   Herbalist   Nutritionist   Homeopath   
Other   Specify:     
2) Approximate total number of chronic patients seeking treatment:     
3) Approximate total number of HIV infected patients seeking treatment:  __________ 
4) Do you recommend the use of TCAM in HIV infected patients? Yes / No 
5) If your answer to question (4) is no, why not? 
                  
                  
6) If your answer to question (4) is 'yes', complete the following table about the type of treatment you offer: 
TCAM Used for:   Cost Approx. 
you  HIV in  
Symptoms in 
HIV Dose for No. of 
recommend general 
(Specify 
symptom)   treatment Patients 
  
 
(tick)           
Herbal:                
Sutherlandia             
Lobostemon               
Echinacea             
African potato (Hypoxis)             
St. Johns Wort             
Ginseng                 
Garlic             
Ayurvedic medicine             
Chinese 
medicine               
Other (please specify):           
              
                  
                  
Lifestyle:                 
Homeopathic               
Prayer/ faith healing             
Meditation/visualization             
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Yoga                 
Exercise               
Reiki                 
Acupuncture               
Massage                 
Chiropractic therapies             
Other (please specify):             
                
                  
                  
Nutritional supplements:             
Multivitamins               
Vitamin E                 
Selenium               
Glutamine                 
Other (please specify)             
                
                  
                  
7) Do you ask patients if they are on any other medication? Yes / No 
8) If your answer to question (7) is yes, do you advise them to stop the other medication? Yes / No 
9) If your answer to question (8) is yes, why do you advise them to stop other medication? 
                  
                  
10) If your answer to question (8) is no, which medication (if known) do your patients take with your 
treatment? 
        Approximate No. of your patients 
Medication Your prescribed treatment using medication and TCAM 
            Together 
            
                  
          
                  
                  
                  
11) Are you aware of any interactions of HIV medication with the treatment that u recommend? Yes / No 
12) Do you believe your treatment can cure HIV? Yes / No 
13) Further comments: 
                  
                  
 
158 
 
 
Appendix 1c 
 
A survey investigating the use of Traditional, Complementary and  
Alternative therapy (TCAM) among adult HIV-infected patients  
Researcher administered patient interview questionnaire 
Study No.   Site No.     Date   
Section A:  
Socio-demographic information 
1) Sex M F 
2) Age   
3) Ethnicity 
Black Coloured Asian White Other 
Specify:      
4) Home language 
Xhosa Zulu  Suthu English Afrikaan Other  
Specify:     
5) Religious affiliation 
African/traditional Christian Muslim Hindu Jewish None Other 
Specify:   
6) Marital status 
Single Currently married Cohabitating Divorced/Separated Widowed 
7) Highest education 
None Primary 
Secondar
y Post school 
8) Residence  
Informal settlements Suburban/Metropolitan areas 
Townshi
p Rural village Farm 
9) Employment situation 
Employed Casually Employed/Part time Unemployed 
Disable
d Student 
10) Main Source of household income 
Formal salary/wages 
Contribution by family 
members Government grant Donation   
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No income Other 
 
Specify:     
      
    
Section B:  
Health Characteristics 
1) How long have you known you are HIV-positive? 
< 3 months 3 - 11 months 
1 - 3 
years 
3 - 5 
years  
> 5 
years 
          
2) What was your latest CD4 count (Cells/mm3)     
3) In your opinion, your current state of health is: 
Very poor Poor Fair Good 
Excelle
nt 
4) Have you been experiencing any abnormal symptoms e.g. headache, nausea etc? Yes / No 
5) If your answer to question (4) is yes, tick the symptoms you are experiencing, and the duration you have been 
experiencing them for 
Symptoms 
You are 
experiencing Duration you have been  
      
 
 experiencing them for 
Nausea               
Vomiting 
              
Loss of appetite           
Diarrhoea 
              
Constipation           
Body pains             
Loss of taste/smell             
Other (please specify): 
          
Section C: 
Clinical management 
1) Are you currently on ARV therapy? Yes / No 
2) If you answered yes to Question (1), which ARVs are you on? 
ARVs Duration since you started 
          
        
 
        
 
  
   
            
2) Are you taking any other medication at the moment? Yes / No 
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3) If you answered yes to question (2), which other medication are you taking? 
Medication 
Duration since you started 
using 
        
            
        
            
4) Have you been counselled by your HCP with regards to self-prescribing? 
Section D: 
Management of HIV with TCAM 
1) Are you using any Traditional, Complementary or Alternative therapy? Yes / No 
2) If you answered 'no' to question (1), you need not complete the rest of the questionnaire. Thank you for your 
participation. 
3) If you answered yes to question (1), please complete the following table 
    
When 
did Prescribed by: Used for: Cost 
you 
start     TCAMP  HIV in  Symptoms in HIV Of 
TCAM you are using using? Self Clinic 
 
general 
(Specify 
symptom) Tx 
          
(Specify)
* 
 
(Tick)       
Herbal:  
 
                
Sutherlandia                 
Lobostemon                   
Echinacea                 
African potato (Hypoxis)                 
St. Johns 
Wort                 
Ginseng                   
Garlic                 
Ayurvedic medicine                 
Chinese medicine                 
Other (please specify):                 
                  
                    
                    
Lifestyle:                   
Homeopathic                 
Prayer/ faith healing                 
Meditation/visualization                 
Yoga                   
Exercise 
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Reiki                   
Acupuncture 
 
                
Massage                   
Chiropractic therapies                 
Other (please specify):                 
                  
                    
                    
Nutritional 
supplements:                 
Multivitamins                 
Vitamin E                   
Selenium                 
Glutamine                   
Other (please specify)                 
                  
                    
                    
* TCAM practitioners include people like traditional healers, herbalists, naturopaths, homeopaths etc 
4) Why do you use complementary and/or alternative therapies? (tick all that apply) 
Reason 
Tick 
 
a) Not satisfied with conventional medicine (medicine from 
clinic)     
b) You believe it improves your health         
c) Family tradition/culture     
d) Reduce side effects of medicine from the clinic       
e) You have more personal control over your health care     
f) You believe it is more 
natural           
g) You are curious     
h) You believe it has anti-HIV properties         
i) Other (specify):             
      
                
                
                
5) How well do you believe your TCAM practitioner has informed you about your HIV disease? (tick where 
appropriate) 
Very poorly informed Poorly informed Fairly informed Well informed 
Very well 
informed 
by TCAM by TCAM by TCAM by TCAM by TCAM 
practitioner practitioner Practitioner Practitioner Practitioner 
6) How much more than your doctor do you trust your TCAM provider to help you manage your condition? (tick 
where appropriate) 
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1 2 3 4 5 
I trust my 
TCAM I trust my TCAM 
practitioner 
practitioner much 
more 
much less 
7) Did you consult your doctor/nurse before starting TCAM? Yes / No 
8) Did your doctor/nurse ever ask you if you were using TCAM? Yes / No 
9) If your answer to question (8) was 'yes', did you agree that you were using TCAM? Yes / No 
10) If your answer to question (9) was 'no', why did you say no? (tick all that 
apply) 
Reason Tick 
You did not feel it was 
necessary     
You felt the doctor/nurse will stop you from using it   
You did not want to go against your culture/tradition   
You wanted to feel in  control of your condition   
It was embarrassing     
Other (specify)         
11) Are you aware of any possible drug interactions of medicines from the clinic with your TCAM? Yes / No 
12) Has anyone in the TCAM system ever exhibited hostility or a lack of respect toward you when you were 
seeking TCAM? 
Yes / No 
13) Do you believe TCAM can cure your HIV? 
14) Do you know of anyone using TCAMs for HIV?  
15) If yes to question 14, do you know which TCAMs they are using? 
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Appendix 2 
Department of Pharmacy 
Faculty of Health Sciences 
NMMU 
Tel: +27 (0)41 504-2128  Fax: +27 (0)41-504-xxxx 
 
Date:    
 
Ref:  
 
Contact person:  XXXX 
 
Dear (Sir/Madam) 
 
You are being asked to participate in this research study which is being conducted as part of 
a Masters degree in Pharmacy at the Nelson Mandela Metropolitan University (NMMU).  
The study aims to determine the extent to which traditional, complementary and alternative 
medicine (TCAM) is being recommended and used in HIV/AIDS patients, prior to and during 
antiretroviral (ARV) treatment. The study is being conducted in the form of surveys in which 
HIV-positive patients, complementary and alternative medicine practitioners and health care 
professionals will be expected to participate. Your participation will be important for the 
study as it will help raise an awareness of the extent to which TCAM is being used in 
HIV/AIDS, prior to and during ARV therapy.  Please feel free to ask the researcher to clarify 
anything that is not clear to you.   
 
To participate, it will be required of you to provide a written consent that will include your 
signature, date and initials to verify that you understand and agree to the conditions. 
 
You have the right to query concerns regarding the study at any time. Telephone numbers of 
the researcher are provided.  Please feel free to call these numbers.    
 
Furthermore, it is important that you are aware of the fact that the ethical integrity of the 
study has been approved by the Research Ethics Committee (Human) of the university. The 
REC-H consists of a group of independent experts that has the responsibility to ensure that 
the rights and welfare of participants in research are protected and that studies are 
conducted in an ethical manner.  Studies cannot be conducted without REC-H’s approval.  
Queries with regard to your rights as a research subject can be directed to the Research 
Ethics Committee (Human), Department of Research Capacity Development, PO Box 77000, 
Nelson Mandela Metropolitan University, Port Elizabeth, 6031. 
 
If no one could assist you, you may write to: The Chairperson of the Research, Technology 
and Innovation Committee, PO Box 77000, Nelson Mandela Metropolitan University, Port 
Elizabeth, 6031. 
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Participation in research is completely voluntary.  You are not obliged to take part in any 
research.  If you choose not to participate in medically related research, your present and/or 
future medical care will not be affected in any way and you will incur no penalty and/or loss 
of benefits to which you may otherwise be entitled. 
 
If you do partake, you have the right to withdraw at any given time, during the study without 
penalty or loss of benefits.   
 
If you fail to follow instructions, or if your medical condition changes in such a way that the 
researcher believes that it is not in your best interest to continue in this study, or for 
administrative reasons, your participation maybe discontinued.  The study may be 
terminated at any time by the researcher, the sponsor or the Research Ethics Committee 
(Human).  
 
Although your identity will at all times remain confidential, the results of the research study 
may be presented at scientific conferences or in specialist publications.  
 
This informed consent statement has been prepared in compliance with current statutory 
guidelines. 
 
Yours sincerely 
 
 
 
 
Imran Lunat 
(Researcher) 
Mobile: 082 062 9963 
E-mail: Imran.lunat@yahoo.com  
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Appendix 3a 
 
                                                                                 UDIPA LIFE & WELLNESS CENTRE 
38 A Cuyler Street 
Cuyler Hospital Grounds 
P. O. Box 832 
Uitenhage 
Tel / Fax 041- 9911892 
 
 
 
 
                                                                                            “Defending your health” 
 
 
TO WHOM IT MAY CONCERN:                    Date: MARCH 2009 
 
 
I, Dr L.M. Naidoo, in my capacity as Director of Udipa Life and Wellness 
Centre, hereby grant permission for your faculty to conduct research studies at 
our centre. We trust that the issue of ethics and confidentiality of all participants 
will be respected.  
We look forward to this partnership and ensure our support wherever possible. 
 
Yours Faithfully 
Dr L. M. Naidoo 
Director 
Udipa Managed Care 
 
Tel. (041 9228272) 
Cellular (083 448 3282) 
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